Drug compounds

By developing novel benzodiazepine derivatives with bicyclic heteroaromatic ring systems, the limited problems of existing anti-RSV treatment methods are solved, and new anti-RSV drugs with strong antiviral activity and good pharmacokinetic properties are provided , better than previous compounds.

CN114555604BActive Publication Date: 2024-11-15PFIZER INC
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202080072206.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-20
Filing Date
2020-08-20
Publication Date
2024-11-15
Estimated Expiration
2040-08-20

AI Technical Summary

Technical Problem

Existing anti-RSV treatments are limited, especially for non-premature and high-risk infants, and the limited utility of existing benzodiazepine inhibitors is urgently needed, with strong antiviral activity and good pharmacokinetic properties. .

Method used

A series of novel benzodiazepine derivatives have five-membered ring structures with bicyclic heteroaromatic ring systems, which are connected to the benzodiazepine ring system through amide groups, providing strong anti-RSV activity and good medicines. Generation dynamics characteristics.

Benefits of technology

These compounds show effective anti-RSV activity and good bioavailability, better than the prior art compounds discussed previously, with potential as new anti-RSV therapeutic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114555604B_ABST
    Figure CN114555604B_ABST
Patent Text Reader

Abstract

Benzodiazepine #imgabs0# derivatives of formula (I): #imgabs1# wherein: R 1 and R 2 wherein each of the R is independently H or halo; (i) T is N, Z is C, #imgabs2# and #imgabs3# are bonds, and #imgabs4# and #imgabs5# do not exist; or (ii) T is C, Z is N, #imgabs6# and #imgabs7# are bonds, and #imgabs8# and #imgabs9# do not exist; R 3 and R 4 Each of the 6 , ‑NR 6 R 7 ,‑COR 8 ,‑C(O)OR 8 ,‑CON(R 8 )2 or ‑R 6 ; R 5 is H or halogen; R 6 and R 7 Each of the above is independently H or a group selected from the following: C1-C6 alkyl, C3-C 10 Cycloalkyl, C6-C 10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, said groups being unsubstituted or substituted; R 8 is H or C1-C6 alkyl, and when there are two, each R 8 are the same or different; n is 0 or 1; and each of V, W, X and Y is N or CH and the other three are CH; and pharmaceutically acceptable salts thereof are inhibitors of RSV and therefore can be used to treat or prevent RSV infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to benzodiazepines Derivatives thereof, and use thereof in treating or preventing respiratory syncytial virus (RSV) infection. Background Art

[0002] RSV is a negative-sense, single-stranded RNA virus of the family Paramyxoviridae. RSV is easily transmitted through secretions of infected people via surfaces or hand-to-hand transfer. Unlike influenza, it is not transmitted through small particle aerosols. After successful vaccination, the incubation period is between 4 and 6 days, during which the virus spreads from the nasopharynx to the lower respiratory tract by fusion with uninfected cells and by shedding of necrotic epithelium. In infants, combined with increased mucus secretions and edema, this can lead to mucus plugging, resulting in hyperinflation and collapse of distal lung tissue - which indicates bronchiolitis. Hypoxia is common, and the ability to eat is often impaired due to respiratory distress. In RSV pneumonia, the inflammatory infiltration of the airways is composed of mononuclear cells and, more generally, involves bronchiolitis, bronchi, and alveoli. The duration and extent of viral shedding have been found to be correlated with clinical symptoms and the severity of the disease.

[0003] RSV is the leading cause of severe respiratory infections in infants and young children worldwide. Although many infants hospitalized with RSV infection are otherwise healthy, morbidity and mortality are highest in premature infants and those with chronic lung or heart disease. Severe RSV infection in infancy can lead to recurrent wheezing for years and is associated with the development of asthma later in life.

[0004] RSV is also a major cause of morbidity and mortality in the elderly as well as in immunocompromised children and adults, and in patients with chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF).

[0005] RSV has a seasonal incidence; it is highly predictable and occurs during the winter in both hemispheres, from September to May in Europe and North America, peaking in December and January, and can occur year-round in tropical countries. It affects >90% of infants and young children by age 2 years, because natural immunity is short-lived; many are reinfected annually. Like influenza, in the elderly, RSV causes approximately 10% of winter hospitalizations and has an associated mortality rate of 10%.

[0006] Current anti-RSV treatment involves the use of a monoclonal antibody to RSV called palivizumab. This use of palivizumab is a preventive rather than a curative treatment for RSV. While this antibody is generally effective, its use is limited to premature infants and high-risk infants. In fact, its limited utility means that many people who need anti-RSV treatment are unable to use it. Therefore, effective alternatives to current anti-RSV treatments are urgently needed.

[0007] Small molecules have also been proposed as inhibitors of RSV. These include benzimidazoles and benzodiazepines. For example, RSV604 (a benzodiazepine with submicromolar anti-RSV activity) is described in Antimicrobial Agents and Chemotherapy, Sept. 2007, 3346-3353 (Chapman et al.). Discovery and initial development of benzodiazepine compounds for RSV Inhibitors are also disclosed in publications including WO2004 / 026843 and WO2005 / 089770 (Arrow Therapeutics Limited); WO2016 / 166546 and WO2018 / 033714 (Durham University); and WO2017 / 015449, WO2018 / 129287 and WO2018 / 226801 (Enanta Pharmaceuticals, Inc.).

[0008] There is a need to identify additional compounds having anti-RSV activity, particularly compounds having a combination of potent antiviral activity and favorable pharmacokinetic properties. Summary of the invention

[0009] It has been discovered that a series of novel benzodiazepines The derivatives have strong anti-RSV activity and good pharmacokinetic and physicochemical properties. Therefore, the present invention provides a compound, which is a benzodiazepine of formula (I) derivative:

[0010]

[0011] in:

[0012] R 1 and R 2 Each of is independently H or halo;

[0013] (i) T is N, Z is C, and is a key, and and does not exist; or (ii) T is C, Z is N, and is a key, and and does not exist;

[0014] R 3 and R 4Each of the 6 、-NR 6 R 7 、-COR 8 、-C(O)OR 8 、-CON(R 8 )2 or -R 6 ;

[0015] R 5 is H or a halogen;

[0016] R 6 and R 7 Each of the above is independently H or a group selected from the following: C1-C6 alkyl, C3-C 10 Cycloalkyl, C6-C 10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, said groups being unsubstituted or substituted;

[0017] R 8 is H or C1-C6 alkyl, when two are present, each R 8 are the same or different;

[0018] n is 0 or 1;

[0019] and one of V, W, X and Y is N or CH, and the other three are CH;

[0020] or a pharmaceutically acceptable salt thereof.

[0021] The compounds of the present invention are linked to benzodiazepines via an amide group. The bicyclic heteroaromatic ring system of the heterocyclic ring system has two N atoms in the five-membered ring. This structural feature is believed to be important to the properties of the compounds discussed further below. DETAILED DESCRIPTION

[0022] When any group, ring, substituent or moiety as defined herein is substituted, it is typically substituted by Q as defined below.

[0023] C 1-6 The alkyl group or moiety is straight chain or branched. 1-6 Alkyl groups are usually C 1-4 Alkyl or C 4-6 Alkyl. C 1-6Examples of alkyl and moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl (i.e. 3-methylbutan-1-yl), tert-pentyl (i.e. 2-methylbutan-2-yl), neopentyl (i.e. 2,2-dimethylpropan-1-yl), n-hexyl, isohexyl (i.e. 4-methylpentan-1-yl), tert-hexyl (i.e. 3-methylpentan-3-yl) and neopentyl (i.e. 3,3-dimethylbutan-1-yl). For the avoidance of doubt, when two alkyl moieties are present in a group, the alkyl moieties may be the same or different. C 1-6 The alkyl group is unsubstituted or substituted, typically by one or more groups Q as defined below. For example, C 1-6 The alkyl group is unsubstituted or substituted with 1, 2 or 3 groups Q as defined below.

[0024] Q is halogen, nitro, -CN, OH, C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, C 1-6 Alkoxyalkyl, unsubstituted C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Haloalkyl, C 1-4 Haloalkoxy, -CO2R"', -NR'2, -SR', -S(=O)R', -S(=O)2R', C3-C 10 Cycloalkyl, 4- to 10-membered heterocyclic, C6–C 10 aryl or 4- to 10-membered heteroaryl, wherein each R' is independently selected from H, C 1-6 Alkyl, C 3-10 Cycloalkyl, 4- to 10-membered heterocyclic, C6–C 10 Aryl and 4- to 10-membered heteroaryl.

[0025] C 1-6 The alkoxy group is straight chain or branched. 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, n-butoxy, sec-butoxy or tert-butoxy. 1-6 Alkoxy groups are unsubstituted or typically substituted by one or more groups Q as defined above.

[0026] C 1-6 The alkylthio group is straight chain or branched. 1-4 Alkylthio, for example methylthio, ethylthio, propylthio, isopropylthio, n-propylthio, n-butylthio, sec-butylthio or tert-butylthio. 1-6 Alkylthio is unsubstituted or typically substituted by one or more groups Q as defined above.

[0027] Halogen or halo is F, Cl, Br or I. Typically, it is F or Cl. 1-6 Alkyl groups can be represented by "C 1-6 "Haloalkyl" means a C 1-6 Similarly, halogen-substituted C 1-6 Alkoxy can be represented by "C 1-6 "Haloalkoxy" means a C group as defined above in which one or more hydrogens are replaced by a halogen group 1-6 Alkoxy. Usually, C 1-6 Haloalkyl or C 1-6 The haloalkoxy group is substituted by 1, 2 or 3 of said halogen atoms. The haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups, such as -CX3 and -OCX3, wherein X is a halogen, for example -CF3, -CCl3, -OCF3 and -OCCl3.

[0028] C 1-6 Hydroxyalkyl is a C substituted with one or more OH groups as defined above. 1-6 Alkyl. Typically, it is substituted with one, two or three OH groups. Preferably, it is substituted with a single OH group.

[0029] C 1-6 Alkoxyalkyl is a C 1-6 Alkoxy substituted C as defined above 1-6 For example, it can be methoxyalkyl or ethoxyalkyl, wherein the alkyl part is C as defined above. 1-6 alkyl.

[0030] C6–C 10 Aryl is an aromatic carbocyclic group containing 6 to 10 carbon atoms. It is a monocyclic ring or a fused bicyclic ring system in which an aromatic ring is fused to another aromatic carbocyclic ring. 10 Examples of aryl groups include phenyl and naphthyl. When substituted, the aryl group is typically substituted by a group Q as defined above, for example by 1, 2 or 3 groups selected from the group Q as defined above. More specifically, substituted aryl groups such as substituted phenyl groups are substituted by 1 or 2 groups selected from the group consisting of C1-C6 alkyl, halo, -OR 8 and -N(R 8 )2, where R 8 is H or C1-C6 alkyl. When there are two, each R 8 Same or different.

[0031] C 3-10 Cycloalkyl is a saturated hydrocarbon ring having 3 to 10 carbon atoms. 3-10Cycloalkyl can be C3-C7 cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Typically it is C3-C6 cycloalkyl, or C4-C6 cycloalkyl, for example cyclobutyl, cyclopentyl or cyclohexyl. In one embodiment, it is cyclobutyl. 3-10 Cycloalkyl is unsubstituted or typically substituted by one or more groups Q as defined above.

[0032] 4- to 10-membered heteroaryl or moiety is a 4- to 10-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms selected from O, N and S. It is monocyclic or bicyclic. Typically, it contains one N atom and 0, 1, 2 or 3 additional heteroatoms selected from O, S and N. It can be, for example, a monocyclic 5- to 7-membered heteroaryl, such as a 5- or 6-membered N-containing heteroaryl. Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxadiazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, imidazolyl and pyrazolyl. Furanyl, thienyl, imidazolyl, pyridinyl and pyrimidinyl are preferred. It can alternatively be a bicyclic heteroaryl, such as an 8- to 10-membered bicyclic heteroaryl. Examples include quinolinyl, isoquinolinyl, quinazolyl, quinoxalinyl, indolyl, isoindolyl, indazolyl, imidazopyridazinyl, pyrrolopyridinyl, pyrazolopyrimidinyl and pyrrolopyrimidinyl. When substituted, the heteroaryl (monocyclic or bicyclic) is typically selected from C 1-4 The alkyl group is substituted with one or more, for example 1, 2, or 3 groups of the group Q as defined above.

[0033] A 4- to 10-membered heterocyclyl is a monocyclic or bicyclic non-aromatic, saturated or unsaturated ring system containing 5 to 10 carbon atoms and at least one atom or group selected from N, O, S, SO, SO2 and CO, more typically N or O. When the ring system is bicyclic, one ring may be saturated and one ring may be unsaturated. Typically, it is a C in which 1, 2 or 3 of the carbon atoms in the ring are substituted by atoms or groups selected from O, S, SO2, CO and NH. 4-10 Ring system. More generally, it is a monocyclic, preferably a monocyclic C4-C6 ring. Examples of 4- to 10-membered heterocyclic groups include azetidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, S,S-dioxothiomorpholinyl, 1,3-dioxolanyl, pyrrolidinyl, imidazolin-2-one, pyrrolidin-2-one, tetrahydrofuranyl and tetrahydropyranyl, piperidine-2,6-dione and piperidine-2-one moieties. In particular, the 4- to 10-membered heterocyclic group can be azetidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl.

[0034] When substituted, the heterocyclic group (monocyclic or bicyclic) is typically selected from unsubstituted C 1-4Alkyl and one or more, for example, 1, 2 or 3 groups of the group Q as defined above are substituted. It can be substituted by a bridgehead atom connecting two, usually two ring carbon atoms in the ring atoms. For example, piperazinyl or morpholinyl can be substituted by a carbon bridgehead. The resulting bicyclic structure can be 2,5-diazabicyclo [2.2.1] heptane or 2-oxa-5-azabicyclo [2.2.1] heptane group, respectively.

[0035] For the avoidance of doubt, while the above definitions of heteroaryl and heterocyclyl refer to "N" atoms which may be present in the ring, it will be apparent to the skilled chemist that any such N atom will be protonated (or will carry a substituent as defined above) if it is attached to each of its adjacent ring atoms via a single bond. Such protonated forms are encompassed by the present definitions of heteroaryl and heterocyclyl.

[0036] In one embodiment of formula (I) as defined above, R 2 Benzodiazepines A halogen substituent at the 9-position of the ring system, in particular F. Examples of such compounds are those of the following formula (I'):

[0037]

[0038] Where R 1 is H or halogen, R 2 is H or halo and the remaining groups and variables are as defined above for formula (I). 1 is H or F and R 2 is H or F. For example, R 1 is H or F and R 2 It's F.

[0039] In one embodiment of formula (I), T is N and Z is C. In this compound, and is the key, and and This compound has the following formula (Ia):

[0040]

[0041] wherein all groups and variables are as defined above for formula (I) or (I').

[0042] In another embodiment of formula (I), T is C and Z is N. In this compound, and is the key, and and This compound has the following formula (Ib):

[0043]

[0044] wherein all groups and variables are as defined above for formula (I) or (I').

[0045] In the above formulae (I), (I'), (Ia) and (Ib), V is usually N, and each of W, X and Y is CH. Examples of such structures include benzodiazepines of the following formula (Ia'): imidazopyridazine and the benzodiazepine of the following formula (Ib') Pyrazolopyrimidine:

[0046]

[0047] In formula (Ia') and (Ib'), R 1 To R 5 Each of and n is as defined above for formula (I) or (I').

[0048] In one embodiment of the compounds of the present invention having any one of the structural formulas (I), (I'), (Ia), (Ib), (Ia') and (Ib') as defined above, R 1 is H or F and R 2 Benzodiazepine F at ring position 9 of the ring system.

[0049] In one embodiment of the compounds of Formula (Ia') and (Ib'), R 1 and R 2 The definitions and ring positions defined above for formula (I') apply. This compound is a benzodiazepine of formula (Ia") Imidazolinone:

[0050]

[0051] Where R 1 To R 5 Wherein each and n are as defined above for formula (I'); and a benzodiazepine of formula (Ib") Pyrazolopyrimidine:

[0052]

[0053] Where R 1 To R 5 Each of and n is as defined above for formula (I').

[0054] In the compounds of the present invention having any of the structural formulas defined above, R 3Usually selected from the following groups: C1-C6 alkyl, C3-C 10 Cycloalkyl, C6-C 10 Aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, which groups are unsubstituted or substituted by one or two groups Q as defined above. For example, R as defined above 3 It may be unsubstituted or substituted by a group selected from the following: C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C1-C6 trifluoroalkyl, halogen, -OR 8 、-N(R 8 )2, where R 8 is H, C1-C6 alkyl or C3-C6 cycloalkyl, and when there are two, each R 8 same or different, and -N(R 9 )2, where R 9 The groups together form a ring selected from morpholine, piperidine, piperazine and pyrrolidine, which ring is unsubstituted or substituted by C1-C6 alkyl.

[0055] In the compounds of the present invention having any of the structural formulas defined above, R 3 More typically, it is a group selected from the group consisting of C1-C6 alkyl, C1-C6 haloalkyl (such as C1-C6 difluoroalkyl or C1-C6 trifluoroalkyl), indoline, phenoxy and phenyl, which group is unsubstituted or substituted by 1, 2 or 3 groups selected from the group consisting of halo, -OR 8 and -N(R 8 )2, where R 8 is H, C1-C6 alkyl or C3-C6 cycloalkyl, and when there are two, each R 8 Same or different.

[0056] In one embodiment of the structural formula as defined above, R 3 is a group of the following formula (II):

[0057]

[0058] wherein R" is H, halo, -OR as defined above 8 or -N(R 8 )2.

[0059] In another embodiment of the formula as defined above, R 3is a 4- to 10-membered heteroaryl, for example selected from pyridyl, pyrrolopyridyl and indazolyl. The 4- to 10-membered heteroaryl is unsubstituted or substituted by a group Q as defined above, for example substituted by a group selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C1-C6 trifluoroalkyl, halogen, -OR 8 、-N(R 8 )2, where R 8 is H, C1-C6 alkyl or C3-C6 cycloalkyl, and when there are two, each R 8 same or different, and -N(R 9 )2, where R 9 The groups together form a ring selected from morpholine, piperidine, piperazine and pyrrolidine, which ring is unsubstituted or substituted by C1-C6 alkyl or by a bridgehead carbon atom connecting two ring atoms.

[0060] R 3 Examples of groups include the following:

[0061]

[0062] In the compounds of the present invention having any of the structural formulas defined above, R 4 is bonded to any available carbon atom in the six-membered ring. Thus, in fact, in the structural formulae (I), (I'), (Ia), (Ib), (Ia') and (Ib') as defined above, when present, the group R 4 Substitutes H in one of the ring CH groups represented by any one of V, W, X and Y. Thus, one of V, W, X and Y is N, CH or CR 4 , while the other three are CH or CR 4 , provided there is only one CR 4 exist.

[0063] In one embodiment of the compounds of the present invention having any of the structural formulas as defined above, V is N, and one of W, X and Y is CR 4 , and the other two are CH. In another embodiment, V is N, Y is CH, and one of W and X is CR 4 And the other one is CH.

[0064] In the compounds of the present invention, R 4 Selected from halogen, -OR 6 、-NR 6 R 7 、-COR 8 、-C(O)OR 8 、-CON(R 8 )2 and -R 6, where R 6 and R 7 Each of the above is independently H or selected from C1-C6 alkyl, C3-C 10 Cycloalkyl, C6-C 10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, which is unsubstituted or substituted, and wherein R 8 is H or C1-C6 alkyl, when there are two, each R 8 Same or different.

[0065] In one embodiment, R 4 Is a halogen, -OR 6 、-NR 6 R 7 Or a group selected from the following: C1-C6 alkyl, C3-C 10 Cycloalkyl, C6-C 10 Aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group is unsubstituted or substituted. When substituted, the group is usually substituted by a group Q as defined above. When R 4 Yes-OR 6 ——Among them, R 6 When substituted by a C1-C6 alkyl group, the substituent may be a C1-C6 alkoxy group such that R 6 is a C1-C6 alkoxyalkyl group. 4 Yes-OR 6 ——Among them, R 6 It is C4-C 10 When R is a heterocyclic group, the heterocyclic group may be, for example, unsubstituted or substituted, for example azetidinyl substituted with a C1-C6 alkyl group such as methyl. 4 Yes-OR 6 ——Among them, R 6 When it is a C1-C6 alkyl group, one or more H atoms in the alkyl group may be replaced by D. For example, R 4 It can be the group –OCD3.

[0066] Usually R 4 is a halogen (e.g. Cl), -OR 6 、-NR 6 R 7 , C1-C6 alkyl, C3-C6 cycloalkyl, phenyl, furanyl, thienyl, imidazolyl, pyridyl, pyrimidinyl, azetidinyl, pyrrolinyl, piperidinyl, piperazinyl or morpholinyl, each of which is unsubstituted or substituted by a group Q as described above. When R 4 When substituted, the preferred substituent is halo or C1-C6 alkyl. 4When R is a substituted C1-C6 alkyl group, it may be a mono-, di- or trihalo-substituted C1-C6 alkyl group, such as a difluoroalkyl group or a trifluoroalkyl group. 4 When it is a substituted azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, the substituent is usually a C1-C6 alkyl group. Another preferred substituent for piperidinyl, piperazinyl and morpholinyl is a bridgehead carbon atom connecting two ring atoms.

[0067] Specific compounds of the present invention include the following:

[0068] 2-[4-(Methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0069] 2-[4-(Methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0070] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0071] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0072] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[4-(propan-2-ylamino)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0073] 2-(1-methyl-2,3-dihydroindole-6-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0074] 2-(2-Fluoro-4-methoxyphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0075] 2-(2-Fluoro-4-propan-2-yloxyphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0076] 2-[2-Fluoro-4-(methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0077] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0078] 6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-methylimidazo[1,2-b]pyridazine-3-carboxamide;

[0079] 6-Chloro-2-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide;

[0080] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-(furan-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0081] 2-(2-Fluoro-5-methylphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0082] 2-(2-Fluoro-5-methylphenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0083] 2-(5-chloropyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide;

[0084] 2-(5-chloropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0085] 2-(6-cyclopropylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0086] 2-(6-Cyclopropylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0087] 2-(5-Cyclopropylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0088] 2-(2-Fluoro-5-methylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0089] 2-(2-Fluorophenyl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0090] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

[0091] 2-(2,4-difluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0092] 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

[0093] 2-(2-Fluorophenyl)-7-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0094] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide

[0095] 2-(2-Fluorophenyl)-5-(morpholin-4-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0096] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide

[0097] 2-(2-Fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide

[0098] 2-(2,3-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0099] 2-(2,3-Difluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0100] 2-(2,6-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0101] 2-(2-Fluoro-4-pyrrolidin-1-ylphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0102] 6-Methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0103] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0104] 2-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0105] 2-(6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0106] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0107] 2-[6-(2-methoxyethyl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0108] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0109] 2-(6-ethoxypyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0110] 2-(6-ethylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0111] 2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0112] 2-(6-ethyl-2-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0113] 2-(6-ethyl-2-methylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0114] 2-(6-propan-2-ylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0115] 2-(6-Propan-2-ylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0116] 2-[2-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0117] 2-[2-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0118] 2-[4-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0119] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1-methylindazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0120] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0121] 2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0122] 2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0123] 2-[6-(3-methylmorpholin-4-yl)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0124] 2-[6-(3-methylmorpholin-4-yl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0125] 2-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0126] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0127] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0128] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-morpholin-4-ylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0129] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0130] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0131] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0132] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0133] 2-[6-(2-Hydroxy-2-methylpropyl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0134] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-fluoropyridin-2-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide

[0135] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-morpholin-4-ylimidazo[1,2-b]pyridazine-3-carboxamide

[0136] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0137] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0138] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0139] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-morpholin-4-yl-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0140] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0141] 2-(2-Fluoro-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0142] 2-(2-methoxy-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0143] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide 2-(2,4-difluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0144] 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0145] 2-(2,4-Difluorophenyl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0146] 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methylimidazo[1,2-b]pyridazine-3-carboxamide

[0147] 6-Methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0148] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0149] 6-(Azetidin-1-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide

[0150] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0151] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-pyridin-3-ylimidazo[1,2-b]pyridazine-3-carboxamide

[0152] 6-methyl-2-(2-methylpyridin-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0153] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(2-methylpyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0154] 2-(3-Fluoropyridin-4-yl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0155] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(3-fluoropyridin-4-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide

[0156] 2-(5-fluoropyridin-3-yl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0157] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-fluoropyridin-3-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide

[0158] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(5-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0159] 6-Methyl-2-(6-morpholin-4-ylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0160] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0161] 6-(Ethylamino)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide

[0162] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0163] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(1-methylazetidin-3-yl)oxyimidazo[1,2-b]pyridazine-3-carboxamide

[0164] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-(1-methylazetidin-3-yl)oxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0165] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(2-methoxyethoxy)imidazo[1,2-b]pyridazine-3-carboxamide

[0166] 6-Methoxy-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0167] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenyl-6-(trideuterated methoxy)imidazo[1,2-b]pyridazine-3-carboxamide

[0168] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0169] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenyl-6-(trideuterated methoxy)imidazo[1,2-b]pyridazine-3-carboxamide

[0170] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methoxyimidazo[1,2-b]pyridazine-3-carboxamide

[0171] 6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide

[0172] 6-Chloro-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0173] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-(5-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0174] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(3-fluoropyridin-4-yl)-6-methoxyimidazo[1,2-b]pyridazine-3-carboxamide

[0175] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-(6-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0176] 2-(6-ethylpyridin-3-yl)-6-methoxy-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0177] 6-Ethoxy-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0178] 2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-6-( 2 H3)Methoxyimidazo[1,2-b]pyridazine-3-carboxamide

[0179] 2-(6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0180] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-2-{6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl}pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0181] N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1H-indazol-5-yl)imidazo[1,2-b]pyridazine-3-carboxamide and pharmaceutically acceptable salts thereof.

[0182] The compounds of the present invention may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention, including but not limited to, diastereomers, enantiomers and atropisomers, and mixtures thereof such as racemic mixtures, are intended to form part of the present invention. Compounds of formula (I) containing one or more chiral centers may be used in enantiomerically or diastereomerically pure form, or in the form of isomeric mixtures.

[0183] The present invention includes all geometric and positional isomers of the compounds of the present invention as defined above. For example, if the compounds of the present invention are incorporated into double bonds or fused rings, cis and trans forms and mixtures thereof are included within the scope of the present invention. Both single positional isomers and mixtures of positional isomers are also within the scope of the present invention.

[0184] The compounds of the present invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the present invention embrace both solvated and unsolvated forms.

[0185] The compounds of the present invention may exist in different tautomeric forms, and all of these forms are included within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be mutually converted via a low energy barrier. For example, proton tautomers (also referred to as proto-tautomers) include interconversions via proton migration, such as keto-enol tautomerism. Valence tautomers include interconversions by reorganization of some bonded electrons.

[0186] The compounds of the present invention can be prepared by the synthetic methods described in the examples below, or analogously thereto by using appropriate starting materials and methods with which the skilled chemist will be familiar.

[0187] Benzodiazepine of formula (I) The derivatives can be converted into their pharmaceutically acceptable salts, and the salts can be converted into free compounds by conventional methods. The derivative can be contacted with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt. A pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.

[0188] Pharmaceutically acceptable acids include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, diphosphoric acid, hydrobromic acid or nitric acid and organic acids such as citric acid, fumaric acid, maleic acid, malic acid, ascorbic acid, succinic acid, tartaric acid, benzoic acid, acetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or p-toluenesulfonic acid. Pharmaceutically acceptable bases include alkali metal (e.g., sodium or potassium) and alkaline earth metal (e.g., calcium or magnesium) hydroxides and organic bases such as alkylamines, aralkylamines and heterocyclic amines.

[0189] Compounds of the present invention have been found to be inhibitors of respiratory syncytial virus (RSV) in biological tests. They possess effective anti-RSV activity with a combination of good bioavailability and physicochemical properties. This combination of properties makes the compounds useful in treatment and superior to many compounds disclosed in the prior art documents discussed previously as candidate drugs.

[0190] Therefore, the present invention further provides a benzodiazepine of formula (I) as described above A compound of a derivative, or a pharmaceutically acceptable salt thereof, for use in a method of treating the human or animal body by therapy.

[0191] The present invention also provides the compound of the present invention as defined above, which is used for treating or preventing the method for RSV infection. Still further, the present invention provides the purposes of the compound of the present invention as defined above in the manufacture of a medicine for treating or preventing RSV infection. Therefore, a subject suffering from or susceptible to RSV infection can be treated by including applying the method of the compound of the present invention as defined above to it. Thereby the condition of the subject can be improved or improved.

[0192] RSV infection is respiratory tract infection normally. RSV infection can be children's infection, for example children under ten years old or babies under two years old. In one embodiment, the invention provides compounds as defined above for the RSV infection for the treatment or prevention of pediatric patients. Alternatively, infection can be the infection of mature or elderly adults, for example adults over 60 years old, adults over 70 years old or adults over 80 years old. The present invention further provides compounds for the RSV infection for the treatment or prevention of elderly patients.

[0193] The RSV infection can be an infection in an immunocompromised individual or an individual with COPD or CHF. In another embodiment, the RSV infection is an infection in an uncompromised individual, such as an otherwise healthy individual.

[0194] The compounds of the present invention can be administered in a variety of dosage forms, for example, orally, such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions, or parenterally, for example, intramuscularly, intravenously or subcutaneously. Thus, the compounds can be administered by injection, infusion or by inhalation or atomization. Preferably, the compounds are administered by oral administration.

[0195] The dosage depends on various factors, including the patient's age, body weight and condition and route of administration. The daily dose can vary over a wide range and will be adjusted according to each specific individual need. However, usually, when the compound is administered alone to an adult, the dosage used by each route of administration is 0.0001 to 650 mg / kg, most commonly in the range of 0.001 to 10 mg / kg body weight, such as 0.01 to 1 mg / kg. This dosage, for example, can be given 1 to 5 times a day. For intravenous injection, a suitable daily dose is 0.0001 to 1 mg / kg body weight, preferably 0.0001 to 0.1 mg / kg body weight. The daily dose can be used as a single dose or according to a separate dosage regimen.

[0196] Unit dosage forms such as tablets or capsules will typically contain 1-250 mg of active ingredient. For example, a compound of formula (I) can be administered to a human patient once a day, twice a day, or three times a day at a dosage between 100-250 mg. For example, a compound of formula (I) can be administered to a human patient once a day, twice a day, or three times a day at a dosage between 100-250 mg.

[0197] The compound of formula (I) and its pharmaceutically acceptable salt can be used alone. Alternatively, they can be administered in the form of a pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier. For example, "Pharmaceuticals-The Science of Dosage Form Designs", ME Aulton, Churchill Livingstone, 1988 describes the conventional steps of selecting and preparing suitable pharmaceutical preparations.

[0198] Depending on the mode of administration, the pharmaceutical composition will preferably contain 0.05 to 99%w (weight percent), more preferably 0.05 to 80%w, still more preferably 0.10 to 70%w, and even more preferably 0.10 to 50%w of active ingredient, all weight percentages being based on the total composition.

[0199] The present invention further provides a process for preparing a pharmaceutical composition of the present invention, which comprises mixing a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable adjuvant, diluent or carrier.

[0200] The compounds of the present invention can be administered in a variety of dosage forms. Thus, they can be, for example, administered orally as tablets, lozenges, lozenges, aqueous or oily suspensions, solutions, dispersible powders or granules. The compounds of the present invention can also be administered parenterally by infusion techniques or by inhalation or atomization, whether subcutaneously, intravenously, intramuscularly, intrasternal, transdermally. The compounds can also be administered as suppositories.

[0201] The solid oral form of the pharmaceutical composition of the present invention may contain a diluent, for example, lactose, dextrose, sucrose, cellulose, corn starch or potato starch together with the active compound; a lubricant, for example, silicon dioxide, talc, stearic acid, magnesium stearate or calcium stearate and / or polyethylene glycol; a binder, for example, starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; a dissociating agent, for example, starch, alginic acid, alginate or sodium starch glycolate; an effervescent mixture; a dye; a sweetener; a wetting agent, such as lecithin, polysorbate, lauryl sulfate; and, in general, a non-toxic and pharmacologically inactive substance used in a pharmaceutical preparation. Such a pharmaceutical preparation can be manufactured in a known manner, for example, by mixing, granulating, tabletting, sugar coating or film coating processes.

[0202] Liquid dispersions for oral administration may be syrups, emulsions and suspensions. Syrups may contain, for example, sucrose or sucrose containing glycerol and / or mannitol and / or sorbitol as a carrier.

[0203] Suspension and emulsion can contain for example natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol as carrier.Suspension or solution for intramuscular injection can contain pharmaceutically acceptable carrier together with active compound, for example, sterile water, olive oil, ethyl oleate, glycol such as propylene glycol, and if necessary, an amount of lidocaine hydrochloride.Further suitable carrier for suspension includes sterile water, hydroxypropyl methylcellulose (HPMC), polysorbate 80, polyvinyl pyrrolidone (PVP), aerosol AOT (that is, 1,2-bis (2-ethylhexyloxycarbonyl) sodium ethanesulfonate), pluronic F127 and / or captisol (that is, sulfobutyl ether beta-cyclodextrin).

[0204] For example, the compounds of the invention may be formulated as an aqueous suspension in a carrier selected from:

[0205] (i) 0.5% w / v hydroxypropyl methylcellulose (HPMC) / 0.1% w / v polysorbate 80;

[0206] (ii) 0.67% w / v polyvinylpyrrolidone (PVP) / 0.33% w / v aerosol AOT (sodium l,2-bis(2-ethylhexyloxycarbonyl)ethanesulfonate);

[0207] (iii) 1% w / v pluronic F 127; and

[0208] (iv) 0.5% w / v Polysorbate 80.

[0209] The carrier can be prepared by standard procedures known to those skilled in the art. For example, each of carriers (i) to (iv) can be prepared by weighing the desired amount of excipient into a suitable container, adding about 80% of the final volume of water and magnetically stirring until a solution is formed. The carrier is then made up to volume with water. An aqueous suspension of a compound of Formula I can be prepared by weighing the desired amount of the compound of Formula I into a suitable container, adding 100% of the desired volume of the carrier and magnetically stirring.

[0210] Solutions for injection or infusion may contain, for example, sterile water as a carrier, or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

[0211] The compounds of the present invention can also be administered in combination with other compounds for the treatment of viral infections. Thus, the present invention further relates to combination therapy, wherein the compounds of the present invention or their pharmaceutically acceptable salts or pharmaceutical compositions or preparations comprising the compounds of the present invention are administered simultaneously or sequentially with another therapeutic agent or multiple therapeutic agents or as a combined preparation for the treatment or prevention of viral infections, particularly RSV infections.

[0212] In this document, when the term "combination" is used, it is understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention, "combination" refers to simultaneous administration. In another aspect of the invention, "combination" refers to separate administration. In a further aspect of the invention, "combination" refers to sequential administration. When administration is sequential or separate, a delay in administering the second component should not result in, for example, a loss of the beneficial effects of the combination.

[0213] Suitable therapeutic agents for combination therapy include

[0214] (i) RSV fusion inhibitors

[0215] (ii) Other RSV nucleocapsid (N)-protein inhibitors

[0216] (iii) other RSV protein inhibitors, such as those that inhibit the phosphoprotein (P) protein and the large (L) protein;

[0217] iv) nucleoside or polymerase inhibitors that inhibit L protein;

[0218] (v) anti-RSV monoclonal antibodies, such as F-protein antibodies;

[0219] (vi) immunomodulatory toll-like receptor compounds;

[0220] (vii) other respiratory virus antivirals, such as anti-influenza and anti-rhinovirus compounds; and / or

[0221] (viii) Anti-inflammatory compounds.

[0222] The RSV nucleocapsid (N)-protein plays a key role in viral transcription and replication, mediating the interaction between the genomic RNA and the virally encoded RNA-dependent RNA polymerase. The RSV P- and L-proteins are components of the virally encoded RNA-dependent RNA polymerase of RSV.

[0223] According to a further aspect of the present invention, there is provided a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, in combination with one or more therapeutic agents listed in (i) to (vi) above, for use in treating RSV.

[0224] The following examples are used to further illustrate the present invention. The preparation examples relate to the preparation of starting materials and intermediates used to prepare the example compounds. Neither the examples nor the preparation examples limit the present invention in any way.

[0225] Example

[0226] Reagents were obtained from commercial sources and used without further purification. Anhydrous solvents were purchased from commercial suppliers for supply and storage under N2. Unless otherwise stated, reactions were performed under N2 atmosphere with anhydrous solvents. All temperatures are in °C. TLC was performed on aluminum-backed silica gel plates with a fluorescent indicator at 254 nM (median pore size ). Flash column chromatography was performed using a Biotage Isolera One system (using KP-Sil or Ultra silica gel columns) or an Isco CombiFlash Rf (using FlashPure or RediSep Rf / RediSep Rf gold silica gel columns). Reverse column chromatography was performed on the Isco CombiFlash Rf using a Teledyne Isco RediSep Rf C18 reverse phase column. Ion exchange chromatography was performed on an Isolute SCX-2 silica-propanesulfonic acid solid phase extraction cartridge, washing with an appropriate solvent selected from water, MeCN and MeOH. Elution of basic compounds was performed with NH3 in MeOH (0.7N or 7N, depending on the substrate).

[0227] Preparative HPLC was performed at ambient column temperature by the following methods. HPLC Method 1: Gemini NX (30 mm x 150 mm, 5 μm) column, 42 mL / min and UV detection at 210 nm. HPLC Method 2: Waters X-Select CSH C18 (30 x 100 mm, 5 μm) column, 50 mL / min and UV detection at 215 nm. HPLC Method 3: Waters X-select CDHC18 (19 x 50 mm, 5 μM) column, 42 mL / min and UV detection at all wavelengths using a photodiode array. HPLC Method 4: Waters XSelect CSH C18, (30 x 100 mm, 5 μm) column, 42 mL and UV detection at all wavelengths using a photodiode array. Preparative chiral HPLC was performed at 15 mL / min using ChiralPAK IC (20×250 mm; 5 μm) on a Gilson HPLC system (UV detection at 230 nm) at ambient column temperature. Analytical chiral HPLC was performed at a flow rate of 0.4 mL / min and a 10 min run time using a ChiralPAK IC column (2.1×150 mm; particle size 3 μm) on an Agilent 1100 HPLC (UV detection at 260 nm) at ambient column temperature. Preparative chiral SFC used Waters SFC prep 15 (UV detection by DAD at 210-400 nm; flow rate of 15 mL / min; column temperature of 40° C.; 120 bar back pressure) and Phenomenex Analytical chiral SFC was performed using a Waters SFCACQUITY UPC 2 (UV detection by DAD at 220-400 nm; flow rate 1.5 mL / min; column temperature 40°C; 1750 psi back pressure) with a 3 min run time on a Phenomenex The analysis was performed on a cellulose-4 column (1×25 cm; 5 μm).

[0228] NMR spectra were recorded on a 400 or 500 MHz spectrometer at ambient probe temperature (nominal 298 K). Chemical shifts (δ) are given in ppm and were calibrated by using the residual peak of the solvent as an internal standard (CDCl3, δ = 7.26 ppm; DMSO-d6, δ = 2.50 ppm). Coupling constants are given in Hertz (Hz). An AdvionPlate Express expression L A miniature mass spectrometer records the LRMS.

[0229] LCMS analysis was performed using a Waters Acquity UPLC with a CSH C18 or BEH C18 column (2.1×30 mm) at 40° C. at 0.77 mL / min over 3 or 10 minutes with a linear acetonitrile gradient of 5-95%, as appropriate for the lipophilicity of the compound. The aqueous portion of the mobile phase was 0.1% formic acid (CSH C18 column) or 10 mM ammonium bicarbonate (BEH C18 column). LC-UV chromatograms were recorded between 210 and 400 nm using a Waters Acquity photodiode array detector. Mass spectra were recorded using a Waters Acquity QDa detector with ESI switched between positive and negative ion modes.

[0230] Method A: 3min acid method

[0231] Method B: 3min alkaline method

[0232] Method C: 10 min acid method

[0233] Method D: 10 min alkaline method

[0234] Method E: 1 min alkaline method

[0235] Method F: 1 min acid method

[0236] Preparation Example (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine was prepared using the methods described in WO / 2004 / 026843, WO / 2005 / 090319 and WO / 2017 / 015449 -2-one and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine -2-Keto.

[0237] abbreviation

[0238]

[0239] Preparation Example

[0240] 1A Ethyl-5-amino-3-bromo-1H-pyrazole-4-carboxylate

[0241]

[0242] A solution of N-bromosuccinimide (13.77 g, 77.34 mmol) in MeCN (270 mL) was added dropwise over 25 min to a cooled (0 °C) solution of ethyl 5-amino-1H-pyrazole-4-carboxylate (10.00 g, 64.45 mmol) in THF (250 mL). The reaction was allowed to reach rt and stirred overnight. The reaction mixture was adsorbed onto silica gel, the volatiles were removed under reduced pressure, and the residue was purified by column chromatography [10-50% (EtOH:CH2Cl2:NH4OH in CH2Cl2; 50:8:1)] to give a beige solid, which was triturated with CH2Cl2 (~20 mL) to give a white solid (5.93 g, 39%). LRMS (APCI+) m / z 234.1 / 236.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 12.16 (s, 1H), 6.25 (s, 2H), 4.18 (q, J=7.1Hz, 2H), 1.25 (t, J=7.1Hz, 3H).

[0243] 2A 2-Bromopyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0244]

[0245] A solution of Intermediate 1A (2.27 g, 9.70 mmol) and 1,1,3,3-tetramethoxypropane (1.93 mL, 11.64 mmol) in AcOH (33.9 mL) was heated at 70 °C for 68 h. After cooling to rt, the volatiles were removed under reduced pressure and the residue was dissolved in EtOAc (50 mL) and neutralized with saturated aqueous NaHCO3 until pH≈7. The mixture was extracted with CH2Cl2 (3×50 mL) and the combined organics were dried (Na2SO4) and concentrated in vacuo. The residue was purified by column chromatography (0 to 3% MeOH in CH2Cl2) to give a beige solid (2.31 g, 88%). LCMS (Method A): m / z 292.0 [M+Na] at 0.93 min + . 1 HNMR (500MHz, DMSO-d6) δ9.24 (dd, J=7.0, 1.8Hz, 1H), 8.86 (dd, J=4.3, 1.8Hz, 1H), 7.33 (dd, J=6.9, 4.2Hz, 1H), 4.33 (q, J=7.1Hz, 2H), 1.33 (t, J=7.1Hz, 3H).

[0246] 3A 2-Bromo-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0247]

[0248] A solution of Intermediate 1A (877 mg, 3.750 mmol) and 4,4-dimethoxybutan-2-one (0.99 mL, 7.490 mmol) in toluene (6.3 mL) was heated at 100° C. for 19 h. The volatiles were removed under reduced pressure and the residue was purified by column chromatography (30-57% EtOAc in heptane) to give a white solid (539 mg, 51%). 1 H NMR (400MHz, DMSO-d6) δ9.07 (d, J=7.1Hz, 1H), 7.21 (d, J=7.1Hz, 1H), 4.30 (d, J=7.1Hz, 2H), 2.62 (s, 3H), 1.32 (t, J=7.1Hz, 3H). LRMS(APCI+)m / z 240.2[M-OCH2CH3] +

[0249] 4A 6-bromo-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0250]

[0251] 5-amino-3-methyl-1H-pyrazole-4-carboxylic acid ethyl ester (1.64g, 9.69mmol) and AcOH (8.32mL, 145.41mmol) are added to a solution of 2-bromomalonaldehyde (1.50g, 9.94mmol) in EtOH (19.4mL), and heated at 75°C overnight. Volatiles are removed under reduced pressure, CH2Cl2 (75mL) and saturated NaHCO3 aqueous solution (50mL) are added, and the aqueous layer is extracted with CH2Cl2 (2×50mL). The combined organic extracts are washed with saturated NaHCO3 aqueous solution and brine (each 25mL), dried (Na2SO4) and the solvent is removed under reduced pressure. Purification by column chromatography (18-50% EtOAc in heptane) gives a white solid (1.98g, 72%). 1 H NMR (400MHz, DMSO-d6) δ9.65 (d, J=2.2Hz, 1H), 8.85 (d, J=2.2Hz, 1H), 4.30 (q, J=7.1Hz, 2H), 2.60 (s, 3H), 1.31 (t, J=7.1Hz, 3H). LRMS(APCI+)m / z 238.1[M-OCH2CH3] +

[0252] 5A 3-Fluoro-N-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

[0253]

[0254] Sodium triacetoxyborohydride (268 mg, 1.27 mmol) was added to a solution of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (300 mg, 1.27 mmol), formaldehyde (0.1 mL, 1.33 mmol) and AcOH (0.11 mL, 1.90 mmol) in CH2Cl2 (6 mL) and stirred at rt for 3 h. Additional AcOH (0.11 mL, 1.90 mmol) and sodium triacetoxyborohydride (268 mg, 1.27 mmol) were added and the reaction was stirred at rt overnight. The reaction mixture was partitioned between CH2Cl2 (10 mL) and water (10 mL), separated, and the organic layer was passed through a hydrophobic frit and the solvent removed under reduced pressure. The residue was purified by column chromatography (0-100% EtOAc in isohexane) to give a yellow solid (100 mg, 28%). LCMS (Method A) m / z 252.2 [M+H] at 1.48 min + (ES+).

[0255] 6A 2-phenylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0256]

[0257] A mixture of intermediate 2A (300 mg, 1.11 mmol), phenylboronic acid (167 mg, 1.37 mmol) and K2CO3 (464 mg, 3.36 mmol) in 1,4-dioxane: water (2:1, 3.0 mL) was degassed with N2 for 5 min. Pd(PPh3)4 (192 mg, 0.170 mmol) was added and the reaction mixture was further degassed with N2 for 5 min and then heated to 100 °C overnight. The reaction was cooled to rt, diluted with CH2Cl2 (10 mL), and the organic layer was washed with brine (3×10 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by column chromatography (0-80% EtOAc in hexanes) to give a yellow solid (111 mg, 36%). LCMS (Method A) m / z 222 [M+H] at 1.13 min + (ES+). 1H NMR (500MHz, CDCl3) δ8.79 (dd, J=4.2, 1.8Hz, 1H), 8.75 (dd, J=6.9, 1.9Hz, 1H), 7.79-7.75 (m, 2H ), 7.49-7.45 (m, 3H), 7.03 (dd, J=6.9, 4.1Hz, 1H), 4.38 (q, J=7.1Hz, 2H), 1.29 (t, J=7.1Hz, 3H).

[0258] The following intermediate compounds were prepared by similar procedures as described for Intermediate 6A. Examples 6M and 6N were prepared from the corresponding pinacol boronic acid esters. Example 6O was prepared using 2 eq. of (2,3-difluorophenyl)borous acid.

[0259] Table 1 - Examples prepared via the Suzuki procedure

[0260]

[0261]

[0262]

[0263]

[0264] 6P 2-(2-Fluorophenyl)-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0265]

[0266] A solution of intermediate 24C (149 mg, 0.386 mmol), 2-fluorophenylboronic acid (141 mg, 1.00 mmol) and K2CO3 (161 mg, 1.162 mmol) in 1,4-dioxane / water (2:1, 1.9 mL) was sparged with N2 for ~5 minutes. Pd(PPh3)4 (134 mg, 0.116 mmol) was added and the reaction was heated at 100 °C overnight. The reaction mixture was diluted with CH2Cl2 (25 mL) and acidified with AcOH (pH≈4). The mixture was purified by ion exchange chromatography (2 g SCX-2). The resulting solution was concentrated under reduced pressure to give a brown solid (124 mg, 73%). LCMS (Method A) m / z 396.4 [M+H] at 0.74 min + (ES+). 1H NMR (500MHz, CDCl3) 8.33 (d, J=7.6Hz, 1H), 7.58-7.50 (m, 1H), 7.46-7.38 (m, 1H), 7.24 (t , J=7.6Hz, 1H), 7.15(t, J=9.1Hz, 1H), 6.29-6.18(m, 1H), 4.28-4.18(m, 2H), 4.04-3.92( m, 1H), 3.86-3.73 (m, 1H), 3.62-3.50 (m, 1H), 3.21-3.03 (m, 1H), 2.61 (s, 3H), 2.55-2.46 (m, 1H), 2.26-2.12 (m, 1H), 2.05-1.93 (m, 1H), 1.40-1.31 (m, 1H), 1.19 (t, J=7.1Hz, 3H).

[0267] 7A 2-(2-Fluorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0268]

[0269] Prepared from Intermediate 3A by a similar procedure as described for Intermediate 6A. 1 H NMR (400MHz, DMSO-d6) δ9.15 (d, J=7.1Hz, 1H), 7.60-7.49 (m, 2H), 7.37-7.28 (m, 2H), 7.22 ( d, J=7.1Hz, 1H), 4.13 (q, J=7.1Hz, 2H), 2.64 (s, 3H), 1.08 (t, J=7.1Hz, 3H).LRMS(APCI+)m / z 254.3[M-OCH2CH3] +

[0270] 8A 6-(Furan-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0271]

[0272] A solution of intermediate 4A (200 mg, 0.70 mmol), furan-3-boronic acid (118 mg, 1.06 mmol) and K2CO3 (292 mg, 2.11 mmol) in 1,4-dioxane / water (3:1; 3.52 mL) in a microwave reaction vial was degassed with N2 for ~10 min. Pd(dppf)Cl2 (39 mg, 0.05 mmol) was added and the sealed vial was heated at 80 °C for 16 h. The reaction was cooled to rt, diluted with EtOAc and filtered through a glass microfiber filter paper. The mixture was filtered through a pad of 4-nitropropene and washed with EtOAc. The solvent was removed under reduced pressure and the residue was purified by column chromatography (18-70% EtOAc in heptane). The resulting solid was triturated with cold (0° C.) EtO / heptane (1:1), followed by trituration with heptane (2×), and dried under reduced pressure to give a pink solid (85 mg, 45%). 1 HNMR (400MHz, DMSO-d6) δ9.50 (d, J=2.2Hz, 1H), 9.14 (d, J=2.2Hz, 1H), 8.45-8.43 (m, 1H), 7.85 (t, J=1.7Hz, 1H), 7.19 (dd, J=1.9, 0.9Hz, 1H), 4.30 (q, J=7.1Hz, 2H), 2.61 (s, 3H), 1.33 (t, J=7.1Hz, 3H).LRMS (APCI+)m / z 226.2[M-OCH2CH3] +

[0273] 9A 2-(2-Fluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0274]

[0275] A solution of intermediate 6B (124 mg, 0.320 mmol) and LiOH (1.5M aq; 0.9 mL, 1.350 mmol) in 1:1 THF / MeOH (4 mL) was stirred at rt overnight. The reaction mixture was diluted with water (20 mL) and washed with EtOAc (2×25 mL). The aqueous layer was acidified by dropwise addition of 1M HCl(aq) until pH≈2 and then extracted with CHCl3 / iPrOH (3:1; 3×25 mL). The combined organic extracts were dried (Na2SO4) and the solvent removed under reduced pressure to give a yellow solid (48 mg, 56%). LCMS (Method A) m / z 280.4 [M+Na] at 0.82 min + . 1 H NMR (500MHz, DMSO-d6) 12.19 (br s, 1H), 9.29 (dd, J=6.9, 1.8Hz, 1H), 8.84 (dd, J=4.2, 1.8Hz, 1H), 7.63-7.49 (m, 2H), 7.36-7.26 (m, 2H).

[0276] The following intermediate compounds were prepared by similar procedures as described for Intermediate 9A.

[0277] Table 2 - Preparation Examples via General Ester Hydrolysis Procedure

[0278]

[0279]

[0280]

[0281] 9K 6-Methyl-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxylic acid

[0282]

[0283] Prepared by a similar procedure as described for Intermediate 9A with heating at 40°C. LCMS (Method A) m / z 322.7 [M+H] at 1.03 min + . 1 H NMR (500MHz, DMSO-d6) 13.48 (s, 1H), 9.30 (d, J = 2.0Hz, 1H), 9.03 (d, J = 2.2Hz, 1H ), 8.62-8.58 (m, 1H), 8.24 (d, J=9.3Hz, 1H), 7.44 (d, J=9.3Hz, 1H), 2.62 (s, 3H).

[0284] 10A 2-(2-Chlorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0285]

[0286] A mixture of intermediate 9G (250 mg, 1.03 mmol), 2-chlorophenylboronic acid (170 mg, 1.08 mmol) and K2CO3 (432 mg, 3.13 mmol) in 1,4-dioxane:water (2:1, 3.0 mL) was degassed with N2 for 5 min. Pd(PPh3)4 (119 mg, 0.100 mmol) was added and the reaction mixture was further degassed with N2 for 5 min and then heated to 100°C overnight. The reaction was cooled to rt and concentrated under reduced pressure. NaOH (2M aq; 30 mL) was added and the solution was washed with MTBE (3×50 mL). The aqueous solution was acidified with 1M aq.HCl (pH≈2) and extracted with CHCl3 / iPrOH (3:1; 3×50 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to give a white solid (105 mg, 30%). LCMS (Method A) at 0.86 min m / z 255.99 [M-OCH2CH3] + .

[0287] 11A 2-(2-Fluorophenyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0288]

[0289] A solution of Intermediate 7A (222 mg, 0.740 mmol) and LiOH (1M aq, 2.23 mL, 2.230 mmol) in THF / MeOH (3:1; 3.7 mL) was heated at 50°C for 16 h. The volatiles were removed under reduced pressure and the residue was triturated with Et2O, acidified with HCl (1M; 2.2 mL) and saturated aqueous NH4Cl (5 mL) and extracted with MeOH / CH2Cl2 (1:4; 4×15 mL). The combined organic extracts were washed with brine (5 mL), dried (MgSO4) and the solvent removed under reduced pressure to give a pale yellow solid (151 mg, 75%). 1 H NMR(400MHz, DMSO-d6)δ12.16(br s, 1H), 9.12 (d, J = 7.1Hz, 1H), 7.57-7.48 (m, 2H), 7.33-7.27 (m, 2H), 7.19 (d, J = 7.1Hz, 1H), 2.64 (s, 3H). LRMS (APCI+) m / z272.2 [M+H] + .

[0290] The following intermediate compounds were prepared by similar procedures as described for Intermediate 11A.

[0291]

[0292]

[0293] 11D 2-(2-Fluorophenyl)-5-morpholin-4-ylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0294]

[0295] A solution of Intermediate 26D (192 mg, 0.518 mmol) and LiOH (1M aq, 2.205 mL, 2.205 mmol) in THF / MeOH (3:1; 2.58 mL) was heated at 50°C for 19 h. Additional LiOH (1M aq, 1.036 mL, 1.036 mmol) was added and the reaction was heated for 23 h. A similar workup as described for Intermediate 11A followed by trituration with EtO gave an off-white solid (158 mg, 58%). 1H NMR (400MHz, DMSO-d6) δ11.57 (s, 1H), 8.79 (d, J=7.9Hz, 1H), 7.52-7.44 (m, 2H), 7.29 -7.21(m, 2H), 6.91(d, J=7.9Hz, 1H), 3.82-3.66(m, 8H).LRMS(APCI+)m / z343.1[M+H] + .

[0296] 11E 2-(2-Fluorophenyl)-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0297]

[0298] Prepared by analogy to the procedure described for intermediate 11D. 1 H NMR (400MHz, DMSO-d6) δ11.42 (s, 1H), 8.75 (d, J=7.7Hz, 1H), 7.54-7.44 (m, 2H), 7.32-7. 22(m, 2H), 6.59(d, J=7.8Hz, 1H), 3.68-3.49(m, 4H), 2.08-1.89(m, 4H).LRMS(APCI+)m / z 327.2[M+H] + .

[0299] 12A 6-(Furan-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0300]

[0301] A solution of ethyl 6-(furan-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate intermediate 6A and LiOH (1 Maq; 0.94 mL, 0.94 mmol) in THF / MeOH (3:1, 4 mL) was heated at 50 °C for 2 h and then at 40 °C for 48 h. The volatiles were removed under reduced pressure and coarsely triturated with Et2O, then acidified to pH≈2 with HCl (1 Maq, 0.8 mL) and sat.aq.NH4Cl (5 mL) and extracted with EtOAc / EtOH (~3:1; 3×25 mL). The combined organic extracts were washed with brine (5 mL), dried (Na2SO4) and the solvent removed under reduced pressure. The residue was suspended in water, filtered, washed with water and the obtained precipitate was dried under reduced pressure to give the crude product as a light brown solid (56 mg, 74%). 1H NMR(400MHz, DMSO-d6)δ12.30(br s, 1H), 9.48 (d, J = 2.3Hz, 1H), 9.08 (d, J = 2.3Hz, 1H), 8.45 (s, 1H), 7.85 (s, 1H), 7.19 (s, 1H), 2.60 (s, 3H). LRMS (APCI+) m / z 244.2 [M+H] + .

[0302] 13A 2-Chloro-3-(2-fluorophenyl)-3-oxopropionic acid ethyl ester

[0303]

[0304] At 0°C, a solution of (2-fluorobenzoyl)ethyl acetate (0.43 mL, 2.38 mmol) in MTBE (1 mL) was added dropwise to a stirred solution of sulfuryl chloride (0.21 mL, 2.62 mmol) in MTBE (5 mL), and the reaction was stirred at rt for 2 h. Additional sulfuryl chloride (0.08 mL, 0.95 mmol) was added, and the reaction was stirred at rt overnight. The reaction was quenched with saturated NaHCO aqueous solution (60 mL) and EtOAc (60 mL) and stirred for 30 min. The organic layer was separated, washed with brine (30 mL), dried (MgSO ) and concentrated under reduced pressure to give a yellow oil (346 mg, 55%). 1 H NMR (500MHz, CDCl3) δ7.95 (td, J=7.6, 1.9Hz, 1H), 7.65-7.57 (m, 1H), 7.33-7.26 (m, 1H), 7.24-7.14 (m, 1H), 5.63 (s, 1H), 4.30 (q, J=7.1 2H), 1.27 (t, J=7.1Hz, 3H).

[0305] 14A Ethyl-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxylate

[0306]

[0307] A solution of pyridazin-3-amine (201 mg, 2.110 mmol) and intermediate 13A (0.27 mL, 2.640 mmol) in EtOH (4 mL) was heated to 100 °C for 2 h by MWI. The reaction mixture was cooled to rt, evaporated in vacuo and the residue was purified by column chromatography (0-100% EtOAc in isohexane) to give a yellow solid (70 mg, 9%). LCMS (Method A) m / z 286.01 [M+H] at 1.13 min + . 1H NMR (500MHz, DMSO-d6) δ8.77 (dd, J=4.5, 1.7Hz, 1H), 8.33 (dd, J=9.3, 1.7Hz, 1H), 7.69 (td, J=7.5 , 1.8Hz, 1H), 7.58-7.48 (m, 2H), 7.38-7.29 (m, 2H), 4.23 (q, J=7.1Hz, 2H), 1.11 (t, J=7.1Hz, 3H).

[0308] 15A 2-(2-Fluorophenyl)-6-methylimidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0309]

[0310] Prepared by a procedure analogous to that described for Intermediate 14A. LCMS (Method A) m / z 300.14 [M+H] at 1.21 min + . 1 H NMR (500MHz, DMSO-d6) δ8.20 (d, J=9.3Hz, 1H), 7.68 (td, J=7.5, 1.8Hz, 1H), 7.56-7.48 (m, 1H), 7. 42 (d, J=9.3Hz, 1H), 7.37-7.27 (m, 2H), 4.21 (q, J=7.1Hz, 2H), 2.60 (s, 3H), 1.10 (t, J=7.1Hz, 3H).

[0311] 16A 2-(2-Fluorophenyl)-6-methylimidazo[1,2-b]pyridazine-3-carboxylic acid

[0312]

[0313] Prepared from Intermediate 15A by a procedure similar to that described for Intermediate 9A, heating at 40 °C for -18 h. LCMS (Method A) m / z 272.04 [M+H] at 0.86 min + . 1 H NMR (500MHz, DMSO-d6) δ13.01 (s, 1H), 8.18 (d, J=9.3Hz, 1H), 7.65 (td, J=7.5, 1.8 Hz, 1H), 7.53-7.45 (m, 1H), 7.39 (d, J=9.3Hz, 1H), 7.34-7.25 (m, 2H), 2.60 (s, 3H).

[0314] 17A 3-Bromo-6-ethyl-2-methylpyridine

[0315]

[0316] Pd(PPh3)4 (576 mg, 0.50 mmol) was added to a cooled (0°C) solution of 3,6-dibromo-2-methylpyridine (2.5 g, 9.96 mmol) in THF (40 mL) under nitrogen, followed by the dropwise addition of diethylzinc (1 M in hexanes; 11.96 mL, 11.96 mmol). The reaction was stirred at 0°C for 1 h and then continued at rt for 16 h. The reaction was quenched with sat.aq.NH4Cl (25 mL), diluted with EtOAc (10 mL) and the separated aqueous layer was extracted with EtOAc (3×20 mL). The combined organic extracts were dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (0-10% EtOAc in isohexane) gave a colorless oil (1.3 g, 62%). LCMS (Method B): m / z 200.1 / 202.1 [M+H] at 1.35 min + . 1 H NMR (500MHz, CDCl3) 7.71 (d, J=8.1Hz, 1H), 6.89 (d, J=8.1Hz, 1H), 2.77 (q, J=7.6Hz, 2H), 2.66 (s, 3H), 1.30 (t, J=7.6Hz, 3H).

[0317] 18A 5-Bromo-6-methyl-N-propan-2-ylpyridin-2-amine

[0318]

[0319] A solution of isopropylamine (5.09 mL, 59.2 mmol) and 3-bromo-6-fluoro-2-methylpyridine (2.5 g, 13.2 mmol) in DMSO (6 mL) was heated at 120°C by MWI for 12 h. The reaction was diluted with water (100 mL), extracted with CH2Cl2 (3 x 15 mL), the combined organics dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (5-50% EtOAc in isohexane) gave a colorless oil (2.30 g, 76%). LCMS (Method B): m / z 229.1 / 231.1 [M+H] at 1.54 min. + . 1 H NMR (500MHz, CDCl3) 7.48 (d, J=8.7Hz, 1H), 6.11 (d, J=8.7Hz, 1H), 4.38 (d, J=7.6Hz, 1H), 3.80-3.74 (m, 1H), 2.47 (s, 3H), 1.23 (d, J=6.4Hz, 6H).

[0320] 18B 5-Bromo-4-methyl-N-propan-2-ylpyridin-2-amine

[0321]

[0322] Prepared by a procedure similar to that described for Intermediate 18A from 5-bromo-2-fluoro-4-methylpyridine (2 g, 10.5 mmol) and isopropylamine (4.52 mL, 52.6 mmol). LCMS (Method B): m / z 229.1 / 231.2 [M+H] at 0.45 min + . 1 HNMR (500MHz, CDCl3) 8.09 (s, 1H), 6.27 (s, 1H), 4.40-4.22 (m, 1H), 3.84 (m, 1H), 2.30 (s, 3H), 1.23 (d, J = 6.4Hz, 6H).

[0323] 19A 5-Bromo-2-(2-methoxyethyl)pyridine

[0324]

[0325] NaH (60% in mineral oil, 109 mg, 2.73 mmol) was added to a cooled (-78°C) solution of 2-(5-bromopyridin-2-yl)ethanol (500 mg, 2.48 mmol) in THF (10 mL), stirred at -78°C for 30 min, then MeI (0.17 mL, 2.73 mmol) was added. The reaction mixture was allowed to reach rt and stirred overnight, then quenched with sat. aq. NH4Cl (5 mL). The separated aqueous layer was extracted with CH2Cl2 (3 x 10 mL), the combined organics were dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (0-30% EtOAc in heptane) gave a colorless oil (401 mg, 68%). LCMS (Method B): m / z 216.5 / 218.5 [M+H] at 1.00 min + . 1 H NMR (500MHz, DMSO-d6) 8.59 (dd, J=2.5, 0.7Hz, 1H), 7.94 (dd, J=8.3, 2.5Hz, 1H), 7.2 9 (dd, J=8.3, 0.7Hz, 1H), 3.66 (t, J=6.6Hz, 2H), 3.22 (s, 3H), 2.93 (t, J=6.5Hz, 2H).

[0326] 20A 1-(5-bromopyridin-2-yl)-2-methylpropan-2-ol

[0327]

[0328] Lithium diisopropylamide (2M in THF / heptane / ethylbenzene, 4.1 mL, 8.20 mmol) was added dropwise to a cooled (-78°C) solution of 5-bromo-2-methylpyridine (1 g, 5.81 mmol) in THF (10 mL). The solution was stirred at -78°C for 20 min, then acetone (5.8 mL, 17.4 mmol) was added dropwise. The reaction was allowed to reach room temperature and stirred for 3 h, then quenched with sat.aq. NH4Cl (40 mL) and extracted with CH2Cl2 (2×50 mL). The combined organic extracts were dried (Na2SO4), concentrated under reduced pressure and purified by column chromatography (0-20% EtOAc in CH2Cl2) to give a colorless oil (435 mg, 32%). LCMS (Method B): m / z 214.1 [M-OH] at 0.95 min + . 1 H NMR (500MHz, CDCl3) δ 8.59 (dd, J=2.5, 0.8Hz, 1H), 7.78 (dd, J=8.3, 2.5Hz, 1H), 7.07 (d, J=8.3Hz, 1H), 2.90 (s, 2H), 1.24 (s, 6H).

[0329] 21A 2-Bromo-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0330]

[0331] A solution of Intermediate 1A (963 mg, 4.11 mmol) and 3-ethoxymethylacrolein (0.5 mL, 4.22 mmol) in AcOH (11.8 mL) was heated at 75 °C for 24 h. After cooling to rt, the volatiles were removed under reduced pressure. The residue was partitioned between EtOAc (50 mL) and saturated aqueous NaHCO3 (50 mL), and the separated aqueous phase was extracted with EtOAc (3×50 mL). The combined organic layers were washed sequentially with saturated aqueous NaHCO3, water, and brine (50 mL each), dried (Na2SO4), and the solvent was removed under reduced pressure. Purification by column chromatography (30-79% EtOAc in heptane) gave a white solid (936 mg, 80%). LRMS (APCI+) m / z 238.0, 240.0 [M-OCH2CH3] + . 1 H NMR (400MHz, DMSO-d6) δ9.11 (d, J=1.1Hz, 1H), 8.76 (d, J=2.2Hz, 1H), 4.31 (d, J=7.1Hz, 2H), 2.36 (d, J=1.1Hz, 3H), 1.32 (t, J=7.1Hz, 3H).

[0332] 22A 2-Bromo-5-oxo-4H-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0333]

[0334] Ethyl 5-amino-3-bromo-1H-pyrazole-4-carboxylate (7.88 g, 30.4 mmol) was added to a suspension of ethyl-3-ethoxyacrylate (6.58 mL, 45.6 mmol) and Cs2CO3 (15.1 g, 46.0 mmol) in DMF (120 mL) at rt, and the resulting mixture was heated at 110°C for 1.5 h. The reaction was cooled to rt, poured into ice-cold water (~500 mL) and acetic acid (3.48 mL, 60.8 mmol), and the reaction vessel was further rinsed with water (~100 mL). The resulting precipitate was collected by filtration, washed with water, and then dried under reduced pressure to give an off-white solid (8.09 g, 87%). LCMS (Method A): m / z 240.0 / 242.5 [M-OCH2CH3] at 0.93 min + . 1 H NMR (500MHz, DMSO-d6) δ 11.77 (s, 1H), 8.49 (d, J=7.9Hz, 1H), 6.16 (d, J=7.9Hz, 1H), 4.30 (q, J=7.0Hz, 2H), 1.28 (t, J=7.0Hz, 3H).

[0335] 23A 2-Bromo-5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0336]

[0337] A solution of intermediate 22A (8.09 g, 26.1 mmol) in POCl (25 mL, 268 mmol) was refluxed for 3 h. The reaction was cooled to rt and the volatiles were removed under reduced pressure. The residue was diluted with CHCl (-200 mL) and slowly (caution: exothermic) poured into saturated aqueous NaHCO (300 mL). The resulting exotherm was controlled by adding ice to the mixture. The phases were separated and the aqueous layer was extracted with CHCl (2 x 200 mL). The combined organics were dried (NaSO) and the solvent removed under reduced pressure to give a grey solid (7.94 g, 94%). LCMS (Method A): m / z 326.6 / 328.5 [M+Na] at 1.18 min + . 1H NMR (500MHz, DMSO-d6) δ9.27 (d, J=7.2Hz, 1H), 7.44 (d, J=7.2Hz, 1H), 4.33 (q, J=7.1Hz, 2H), 1.32 (t, J=7.1Hz, 3H).

[0338] 24A 2-Bromo-5-morpholin-4-ylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0339]

[0340] A solution of Intermediate 23A (200 mg, 0.657 mmol), morpholine (75 μL, 0.857 mmol) and DIPEA (232 μL, 1.306 mmol) in DMF (3.28 mL) was heated at 60 °C in a sealed tube for 7 h. The reaction was cooled to rt, diluted with EtOAc (30 mL) and washed with sat. aq. NH4Cl (3×10 mL). The aqueous washes were neutralized with saturated aqueous NaHCO3 (~20 mL) and extracted with EtOAc (3×25 mL). The combined organic layers were washed sequentially with water (3×30 mL) and brine (30 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (35-100% EtOAc in heptane) gave a white solid (194 mg, 83%). LRMS (APCI+) m / z 354.9 / 356.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 8.70 (d, J=7.9Hz, 1H), 6.88 (d, J=7.9Hz, 1H), 4.19 (t, J=7.1Hz, 2H), 3.80-3.67 (m, 8H), 1.29 (t, J=7.1Hz, 3H).

[0341] 24B 2-Bromo-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0342]

[0343] A solution of intermediate 23A (300 mg, 0.985 mmol), pyrrolidine (107 μL, 1.286 mmol) and DIPEA (232 μL, 1.306 mmol) in DMF (4.23 mL) was heated at 60 °C in a sealed vial for 65 h. The reaction was cooled to rt and quenched with water. The resulting precipitate was collected by filtration, washed with water, then dissolved in EtOAc and washed with water (2×15 mL) and brine (15 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (33-70% EtOAc in heptane) gave a white solid (280 mg, 84%). LRMS (APCI+) m / z 339.0 / 341.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.62 (d, J=7.8Hz, 1H), 6.52 (d, J=7.7Hz, 1H), 4.19 (q, J=7.1Hz, 2H ), 3.59 (t, J=6.7Hz, 2H), 3.49 (t, J=6.7Hz, 2H), 2.07-1.87 (m, 4H), 1.30 (t, J=7.1Hz, 3H).

[0344] 24C 2-Bromo-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0345]

[0346] A solution of intermediate 23A (519 mg, 1.551 mmol), (2R, 5R)-1,2,5-trimethylpiperazine-1,4-diammonium dichloride (390 mg, 1.939 mmol) and DIPEA (1 mL, 5.741 mmol) in DMSO (6.5 mL) was heated at 70 ° C for 66 h. The reaction mixture was cooled to rt, diluted with brine (25 mL), extracted with EtOAc (3×25 mL) and the solvent was removed under reduced pressure. The residue was dissolved in MeOH (5 mL) and purified by ion exchange chromatography (2 g SCX-2). The aqueous portion was also purified by ion exchange chromatography (2 g SCX-2). The combined solution was concentrated under reduced pressure to give a brown solid (444 mg, 59%). LCMS (Method A) m / z 380.3 / 382.6 [M+Na] at 0.59 min + . 1H NMR (500MHz, CDCl3) δ8.15 (d, J=7.7Hz, 1H), 6.33-6.00 (m, 1H), 5.27-5.10 (m, 1H), 4.37 (q, J=7.1Hz, 2H), 3.65 (s, 1H), 3.5 0-3.34 (m, 1H), 3.21-2.76 (m, 2H), 2.61 (s, 1H), 2.49 (s, 3H), 2.15-2.00 (m, 1H), 1.94-1.78 (m, 1H), 1.41 (t, J=7.1Hz, 3H).

[0347] 25A 2-Bromo-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0348]

[0349] 5-Amino-3-bromo-1H-pyrazole-4-carboxylic acid ethyl ester (700 mg, 2.990 mmol), 4,4-dimethoxybutane-2-one (0.48 mL, 3.590 mmol), 70% ethanol (9.00 mL) and concentrated HCl (0.25 mL, 2.99 mmol) were charged into a reaction vial and heated at 140 ° C for 30 min by MWI. The reaction mixture was poured into saturated NaHCO3 aqueous solution (100 mL), stirred for 15 min, and the precipitate was collected by filtration and washed with water. The resulting solid was purified by column chromatography (0-20% CH2Cl2: EtOH: NH3 [50: 8: 1] in CH2Cl2) to give a white solid (568 mg, 669%). LRMS m / z [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 8.74 (d, J=4.4Hz, 1H), 7.28 (dd, J=4.4, 1.0Hz, 1H), 4.33 (q, J=7.1Hz, 2H), 2.75 (d, J=0.8Hz, 3H), 1.33 (t, J=7.1Hz, 3H).

[0350] 26A 2-(2-Fluorophenyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0351]

[0352] A solution of intermediate 21A (264 mg, 0.929 mmol), 2-fluorophenylboronic acid (195 mg, 1.394 mmol) and K2CO3 (389 mg, 2.813 mmol) in 1,4-dioxane / water (2:1, 2.79 mL) was sparged with N2 for about 10 min. Pd(PPh3)4 (149 mg, 0.139 mmol) was added and the reaction was heated at 100°C for 18 h. The reaction was cooled to rt, diluted with CH2Cl2 and passed through a glass microfiber filter paper. Filter through a pad of 4% paraformaldehyde and wash with CH2Cl2. The solvent was removed under reduced pressure and the residue was purified by column chromatography (30-70% EtOAc in heptane) to give a light yellow solid (222 mg, 80%). LRMS (APCI+) m / z 254.1 [M-OCH2CH3] + . 1 H NMR (400MHz, DMSO-d6) δ9.17 (dd, J=2.1, 1.1Hz, 1H), 8.77 (d, J=2.2Hz, 1H), 7.61-7.51 (m, 2 H), 7.36-7.29 (m, 2H), 4.15 (q, J=7.1Hz, 2H), 2.40 (d, J=1.1Hz, 3H), 1.11 (t, J=7.1Hz, 3H).

[0353] The following intermediates were prepared in a similar manner to Intermediate 26A.

[0354]

[0355] 27A 2-(5-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0356]

[0357] Intermediate 2A (502 mg, 1.86 mmol), (5-chloropyridin-3-yl)boronic acid (583 mg, 3.70 mmol), K3PO4 (621 mg, 2.92 mmol), XPhos (63 mg, 0.133 mmol) and XPhos Pd(crotyl)Cl (Pd-170; 122 mg, 0.180 mmol) were charged to a reaction vessel and then sparged with N2 for 5 min. THF (9 mL) and water (3 mL) were added and the reaction mixture was sparged with N2 for 5 min and then heated at 65°C for 3 h. The reaction was cooled to rt, diluted with CH2Cl2 (50 mL) and washed with brine (50 mL). The aqueous layer was extracted with CH2Cl2 (2×50 mL) and the combined organic layers were dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (0-3.5% MeOH in CH2Cl2) gave a yellow solid (409 mg, 70%). LCMS (Method A) at 1.06 min m / z 303.2 [M+H] + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.35 (dd, J=7.0, 1.8Hz, 1H), 8.90 (dd, J=4.2, 1.8Hz, 1H), 8.86 (d, J=1.8Hz, 1H), 8.76 (d, J=2.4Hz, 1H), 8.32 (t, J=2.1Hz, 1H), 7.38 (dd, J=7.0, 4.2Hz, 1H), 4.25 (q, J=7.1Hz, 2H), 1.22 (t, J=7.1Hz, 3H).

[0358] The following intermediates were prepared in a similar manner to Intermediate 27A. Prepare Example 27G from the corresponding boronic acid pinacol ester.

[0359] Table 1 - Preparation examples prepared by Suzuki-Miyaura coupling with Pd-170

[0360]

[0361]

[0362]

[0363] 28A 2-(6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0364]

[0365] XPhos Pd G2 (59 mg, 0.076 mmol) was added to a suspension of intermediate 2A (170 mg, 0.504 mmol), (6-methoxypyridin-3-yl)boronic acid (154 mg, 1.008 mmol) and CsF (348 mg, 2.266 mmol) in 1,4-dioxane:water (4:1; 5 mL), and the reaction mixture was sparged with N2 and then heated at 100 °C overnight. The reaction was cooled to rt, diluted with water and EtOAc (10 mL each), and the separated aqueous layer was extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (20 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (0-100% EtOAc in hexanes) gave a yellow solid (149 mg, 99%). LCMS (Method A) at 1.00 min m / z 299.3 [M+H] + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.30 (dd, J=6.9, 1.8Hz, 1H), 8.85 (dd, J=4.2, 1.8Hz, 1H), 8.54 (dd, J=2.4, 0.8Hz, 1H), 8.07 (dd, J=8.6, 2 .5Hz, 1H), 7.32 (dd, J=6.9, 4.2Hz, 1H), 6.94 (dd, J=8.6, 0.8Hz, 1H), 4.26 (q, J=7.1Hz, 2H), 3.93 (s, 3H), 1.24 (t, J=7.1Hz, 3H).

[0366] The following intermediates were prepared in a similar manner to Intermediate 28A. Prepare Examples 29C and 29D from the corresponding boronic acid pinacol esters.

[0367] Table 2 - Preparation examples prepared by Suzuki-Miyaura coupling with XPhos Pd G2

[0368]

[0369]

[0370] 28E Ethyl 2-(2,6-difluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate

[0371]

[0372] Prepared by a procedure similar to that described for Intermediate 28A from Intermediate 2A (76 mg, 0.276 mmol) and 2,6-difluorophenylboronic acid (440 mg, 2.786 mmol) using Xphos Pd G2 (57 mg, 0.072 mmol) and CsF (169 mg, 1.272 mmol) in 1,4-dioxane:water (3:1; 4 mL). White solid (74 mg, 0.244 mmol). LCMS (Method A) m / z 283.0 [M+H] at 0.49 min + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.35 (dd, J=7.0, 1.7Hz, 1H), 8.91 (dd, J=4.2, 1.8Hz, 1H), 7.68-7.58 (m, 1 H), 7.38 (dd, J=7.0, 4.2Hz, 1H), 7.30-7.22 (m, 2H), 4.15 (q, J=7.1Hz, 2H), 1.09 (t, J=7.1Hz, 3H).

[0373] 29A 2-(2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0374]

[0375] XPhos Pd G2 (59 mg, 0.076 mmol) was added to a suspension of Intermediate 2A (170 mg, 0.504 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (221 mg, 1.00 mmol) and CsF (347 mg, 2.266 mmol) in 1,4-dioxane:water (4:1; 5 mL), the reaction mixture was sparged with N2 and heated at 70°C overnight. The reaction was cooled to rt, re-treated with XPhos Pd G2 (59 mg, 0.076 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (221 mg, 1.01 mmol) and CsF (347 mg, 2.266 mmol) and the reaction was heated to 70°C overnight. Similar workup and purification as described for Intermediate 28A gave a yellow solid (75 mg, 53%). LCMS (Method A) at 0.49 min m / z 283.0 [M+H] + (ES+). 1H NMR (500MHz, DMSO-d6) 9.32 (dd, J=7.0, 1.7Hz, 1H), 8.87 (dd, J=4.2, 1.7Hz, 1H), 8.56 (d, J=5.1Hz, 1H), 7.61-7.57 (m, 1 H), 7.52 (dd, J=5.1, 1.7Hz, 1H), 7.36 (dd, J=7.0, 4.2Hz, 1H), 4.25 (q, J=7.1Hz, 2H), 2.55 (s, 3H), 1.21 (t, J=7.1Hz, 3H).

[0376] 30A 2-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0377]

[0378] XPhos Pd G2 (198 mg, 0.25 mmol) was added to a suspension of Intermediate 2A (1 g, 3.59 mmol), 2-fluoropyridine-5-boronic acid (607 mg, 4.31 mmol) and K3PO4 (1.53 g, 7.21 mmol) in 1,4-dioxane:water (4:1; 10 mL), the reaction mixture was sparged with N2 and heated at 100°C for 4 h. Similar workup and purification as described for Intermediate 28A gave a yellow solid (850 mg, 83%). LCMS (Method A) m / z 287.4 [M+H] at 0.96 min + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.36-9.31 (m, 1H), 8.89 (dd, J=4.2, 1.8Hz, 1H), 8.58 (d, J=2.5Hz, 1H), 8.35 (td, J=8.2, 2.5Hz, 1H), 7.39-7.31 (m, 2H), 4.25 (q, J=7.1Hz, 2H), 1.22 (t, J=7.1Hz, 3H).

[0379] 31A 2-(6-ethylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0380]

[0381] KOAc (633 mg, 6.45 mmol) was added to a suspension of bis(pinacol)diboron (600 mg, 2.36 mmol) and 5-bromo-2-ethylpyridine (400 mg, 2.15 mmol) in dioxane (3.3 mL). The mixture was sparged with N2, Pd(dppf)Cl2 (118 mg, 0.161 mmol) was added, and heated at 100°C for 1 h. The reaction was cooled to rt, diluted with EtOAc (30 mL) and filtered through Celite, washing with EtOAc (40 mL). The filtrate was concentrated under reduced pressure to give a yellow oil (501 mg) and the residue was used directly in the next reaction. A portion of the crude residue (251 mg, 1.08 mmol) was suspended in 1,4-dioxane: water (4: 1; 5 mL) and Intermediate 2A (170 mg, 0.504 mmol) and CsF (347 mg, 2.266 mmol) were added, followed by XPhos Pd G2 (59 mg, 0.076 mmol). The reaction was sparged with N2 for 5 minutes. It was then heated at 100 °C for 2 h. Similar workup and purification as described for Intermediate 28A gave an orange solid (112 mg, 73%). LCMS (Method A) m / z 297.4 [M+H] at 0.66 min + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.32 (dd, J=6.9, 1.8Hz, 1H), 8.86 (dd, J=4.2, 1.8Hz, 1H), 8.79 (dd, J=2.3, 0.9Hz, 1H), 8.05 (dd, J=8.0, 2.3Hz, 1H), 7. 39 (d, J=8.0Hz, 1H), 7.33 (dd, J=6.9, 4.2Hz, 1H), 4.25 (q, J=7.1Hz, 2H), 2.83 (q, J=7.6Hz, 2H), 1.28 (t, J=7.6Hz, 3H), 1.22 (t, J=7.1Hz, 3H).

[0382] The following intermediates were prepared in a similar manner to Intermediate 31A. Preparative Examples 31F and 31G were additionally purified by ion exchange chromatography (SCX-2). The reaction for 31G was heated at 70°C.

[0383] Table 3 - Preparation Examples Prepared by Suzuki-Miyaura Coupling

[0384]

[0385]

[0386]

[0387] 32A 2-(5-cyclopropylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0388]

[0389] Potassium cyclopropyltrifluoroborate (143 mg, 0.964 mmol), K2CO3 (187 mg, 1.353 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos; 29 mg, 0.063 mmol) and Pd(OAc)2 (7.1 mg, 0.031 mmol) were added to a solution of intermediate 27A (95 mg, 0.313 mmol) in toluene (1.7 mL) and water (0.2 mL) under N2, and the reaction was heated at 130°C for 2 h by MWI. The reaction mixture was combined with a second batch with 49 mg of 27A (total input 144 mg, 0.476 mmol). The combined reaction mixture was diluted with CH2Cl2 (25 ml) and washed with brine (25 mL). The aqueous layer was extracted with CH2Cl2 (2×25 mL), the combined organic extracts were dried (Na2SO4), and the solvent was removed under reduced pressure. Purification by column chromatography (0-3% MeOH in CH2Cl2) gave an amber oil (104 mg, 71% combined yield). LCMS (Method A) at 0.80 min m / z 309.3 [M+H] + (ES+). 1 H NMR (500MHz, CDCl3) 8.88-8.83 (m, 1H), 8.83-8.76 (m, 2H), 8.55-8.50 (m, 1H), 7.86-7.81 (m, 1H), 7.10 (dd, J=7.0, 4.1Hz, 1H), 4.41 (q, J=7.1Hz, 2H), 2.07-2.01 (m, 1H), 1.33 (t, J=7.1Hz, 3H), 1.16-1.07 (m, 2H), 0.91-0.80 (m, 2H).

[0390] 33A 2-[6-(Propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0391]

[0392] DIPEA (0.18 mL, 1.04 mmol) and isopropylamine (0.36 mL, 4.22 mmol) were added to a solution of intermediate 30A (240 mg, 0.84 mmol) in DMSO (2 mL) and heated at 100 °C overnight. The reaction mixture was partitioned between EtOAc (10 mL) and sat.aq. NH4Cl (10 mL). The separated aqueous layer was extracted with EtOAc (3×10 mL), and the combined organic layers were washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. Purification by column chromatography (0-100% EtOAc in hexanes) gave a yellow solid (127 mg, 42%). LCMS (Method B): m / z 326.4 [M+H] at 1.06 min + . 1 HNMR (500MHz, DMSO-d6) 9.23 (dd, J=6.9, 1.8Hz, 1H), 8.78 (dd, J=4.2, 1.8Hz, 1H), 8.38 (d, J=2.5Hz, 1H), 7.75 (dd, J=8.7, 2.4Hz, 1H), 7.25 (dd, J=6.9, 4.2Hz, 1H), 6.73 (d, J=7.6Hz, 1H), 6.51 (dd, J=8.8, 0.8Hz, 1H), 4.27 (q, J=7 .1Hz, 2H), 4.14-4.02 (m, 1H), 1.26 (t, J=7.1Hz, 3H), 1.18 (d, J=6.4Hz, 6H).

[0393] The following intermediates were prepared in a similar manner to Intermediate 33A. The reaction of Intermediate 33C was heated at 50 °C for 3 h.

[0394] Table 4 - Preparation Examples Prepared by Suzuki-Miyaura Coupling

[0395]

[0396]

[0397]

[0398] 34A 2-[6-(Ethylamino)-2-fluoropyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0399]

[0400] DIPEA (99 μL, 0.57 mmol) and ethylamine (2M in THF; 583 μL, 1.12 mmol) were added to a solution of intermediate 27E (144 mg, 0.47 mmol) in DMSO (2 mL) and heated at 100° C. for 30 min by MWI. Similar workup as described for intermediate 33A followed by purification by column chromatography (0-2% MeOH in CH2Cl2) gave a yellow solid (84 mg, 52%). LCMS (Method A): m / z 352.3 [M+Na] + at 1.09min. 1 H NMR (500MHz, CDCl3) 8.80 (dd, J=4.2, 1.8Hz, 1H), 8.75 (dd, J=7.0, 1.8Hz, 1H), 7.84-7.78 (m, 1H), 7.04 (d d, J=7.0, 4.2Hz, 1H), 6.37-6.33 (m, 1H), 4.40 (q, J=7.1Hz, 2H), 3.40 (q, J=7.2Hz, 2H), 1.35-1.29 (m, 6H).

[0401] 35A 2-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0402]

[0403] DIPEA (116 μL, 0.67 mmol) and isopropylamine (117 μL, 1.36 mmol) were added to a solution of Intermediate 27E (168 mg, 0.55 mmol) in DMSO (2 mL) and stirred at rt for 4 h, then heated at 40° C. for 1 h. Similar workup as described for Intermediate 33A followed by purification by column chromatography (0-3% MeOH in CH2Cl2) gave a white solid (89 mg, 46%). LCMS (Method A): m / z 344.2 [M+H] at 1.19 min + . 1 H NMR (500MHz, DMSO-d6) 9.24 (dd, J=7.0, 1.7Hz, 1H), 8.80 (dd, J=4.2, 1.8Hz, 1H), 7.67 (dd, J=9.9, 8.3Hz, 1H), 7.27 (dd, J=6.9 , 4.2Hz, 1H), 7.14 (d, J=7.6Hz, 1H), 6.43 (dd, J=8.2, 1.8Hz, 1H), 4.20 (q, J=7.1Hz, 2H), 4.01-3.90 (m, 1H), 1.22-1.15 (m, 9H).

[0404] 36A 2-[6-(3-methylmorpholin-4-yl)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0405]

[0406] A solution of Intermediate 30A (150 mg, 0.49 mmol), 3-methylmorpholine (39 μL mL, 0.50 mmol) and DIPEA (107 μL, 0.62 mmol) in DMSO (2 mL) was heated at 100 °C overnight. Additional 3-methylmorpholine (330 μL, 2.42 mmol) and DIPEA (600 μL, 3.45 mmol) were added and the mixture was heated at 145 °C overnight. The reaction mixture was cooled to rt, diluted with EtOAc (25 mL) and washed with saturated aqueous NaHCO3 (3×25 mL). The organic layer was dried (Na2SO4), the solvent was removed under reduced pressure, and the residue was purified by column chromatography (0-4% MeOH in CH2Cl2) to give a brown oil (140 mg, 65%). LCMS (Method A): m / z 368.4 [M+H] at 0.75 min + . 1 H NMR (500MHz, CDCl3)8.81-8.77(m, 1H), 8.77-8.74(m, 1H), 8.70-8.66(m, 1H), 8.04-8.00(m, 1H), 7.07-7.01(m, 1H), 6.71-6.67(m, 1H), 4.49-4.41 (m, 3H), 4.10-4.04 (m, 1H), 4.00-3.96 (m, 1H), 3.88-3.79 (m, 2H), 3.72-3 .63 (m, 1H), 3.34-3.30 (m, 1H), 1.39 (t, J=7.1Hz, 3H), 1.34-1.30 (m, 3H).

[0407] 37A 2-(1-methylindazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0408]

[0409] NaH (60% dispersion in mineral oil, 55 mg, 1.38 mmol) was added to a cooled (0 °C) solution of intermediate 6N (139 mg, 0.45 mmol) in DMF (2 mL) and the reaction was stirred at 0 °C for 30 min. Methyl iodide (34 μL, 0.54 mmol) was added and the reaction was stirred at rt for 4 h. The reaction was quenched with water (5 mL), diluted with EtOAc (25 mL) and the organic layer was washed with brine (3×25 mL), dried (Na2SO4) and the solvent removed under reduced pressure. Purification by column chromatography (0-2% MeOH in CH2Cl2) gave a white solid (47 mg, 32%). LCMS (Method A): m / z 322.7 [M+H] at 1.00 min + . 1 H NMR (500MHz, CDCl3) 8.81-8.73 (m, 2H), 8.20 (dd, J=1.6, 1.0Hz, 1H), 8.07 (d, J=1.0Hz, 1H), 7.83 (dd, J=8.7, 1.6Hz, 1H ), 7.48 (dt, J=8.8, 1.0Hz, 1H), 7.03 (dd, J=6.9, 4.1Hz, 1H), 4.39 (q, J=7.1Hz, 2H), 4.13 (s, 3H), 1.29 (t, J=7.1Hz, 3H).

[0410] 38A 2-(2-Fluoro-4-pyrrolidin-1-ylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0411]

[0412] 1,4-Dibromobutane (67 μL, 0.57 mmol) was added to a solution of intermediate 6M (170 mg, 0.57 mmol), K2CO3 (156 mg, 1.13 mmol) and KI (45 mg, 1.15 mmol) in MeCN (10 mL) and the reaction was heated to 90 °C for ~3 days. The volatiles were removed under reduced pressure and the residue was partitioned between EtOAc (10 mL) and water (10 mL). The separated aqueous layer was extracted with EtOAc (3×10 mL) and the combined organic layers were washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. Purification by column chromatography (0-100% EtOAc in hexanes) gave an orange solid (120 mg, 49%). LCMS (Method A): m / z 355.1 [M+H] at 1.43 min + . 1H NMR (500MHz, DMSO-d6) 9.24 (dd, J=6.9, 1.8Hz, 1H), 8.78 (dd, J=4.1, 1.8Hz, 1H), 7.25 (dd, J=6.9, 4.2Hz, 1H), 6.45 (dd, J=8.6, 2.3Hz, 1H), 6.39 (dd, J=13.8, 2.3Hz, 1H), 4.19 (q, J=7.1Hz, 2H), 3.31-3.25 (m, 4H), 2.02-1.94 (m, 4H), 1.18 (t, J=7.1Hz, 3H).

[0413] 39A Ethyl 6-ethylpyridine-3-carboxylate

[0414]

[0415] EtMgBr (3.0M solution in EtO; 41 mL, 123 mmol) was added dropwise to a cooled (-75 °C) solution of ethyl 6-chloropyridine-3-carboxylate (15.11 g, 81.41 mmol), iron (III) acetylacetonate (2.99 g, 8.30 mmol) and 1-methylpyrrolidin-2-one (11 mL, 114.3 mmol) in THF (400 mL). The mixture was stirred at -75 °C for 1 h, then allowed to warm to 0 °C and quenched by adding water (250 mL) dropwise. The resulting mixture was extracted with EtOAc (3 × 250 mL), and the combined organic layers were concentrated under reduced pressure. The residue was diluted with EtOAc (250 mL), washed with brine (3 × 250 mL), dried (Na2SO4), and the solvent was removed under reduced pressure. Purification by column chromatography (0-15% EtOAc in isohexane) gave a yellow oil (13.45 g, 90%). LCMS (Method A) m / z 180.3 [M+H]+ (ES+) at 0.98 min. 1 H NMR (500MHz, DMSO-d6) 8.99 (d, J=2.3Hz, 1H), 8.19 (dd, J=8.1, 2.3Hz, 1H), 7.43 (d, J=8.1Hz, 1 H), 4.33 (q, J=7.1Hz, 2H), 2.83 (q, J=7.6Hz, 2H), 1.32 (t, J=7.1Hz, 3H), 1.24 (t, J=7.6Hz, 3H).

[0416] 40A 6-Ethylpyridine-3-carboxylic acid

[0417]

[0418] A solution of intermediate 39A (13.45 g, 73.30 mmol) and LiOH (9.22 g, 219.67 mmol) in MeOH:THF:water (1:1:1; 23 mL) was stirred at rt overnight. The reaction mixture was acidified (pH≈4-5) by dropwise addition of 1 M aq. HCl and extracted with CHCl3 / iPrOH (3:1; 3×250 mL). The combined organic layers were dried (Na2SO4) and the solvent was removed under reduced pressure. The aqueous phase was acidified (pH≈3-4) by dropwise addition of 1 M aq. HCl and extracted with CHCl3 / iPrOH (3:1; 3×250 mL). The combined organic layers were dried (Na2SO4) and the solvent was removed under reduced pressure and combined with the residue from the previous organic extract to give an off-white solid (8.05 g, 71%). LCMS (Method A) m / z 152.4 [M+H]+ (ES+) at 0.26 min. 1 HNMR (500MHz, DMSO-d6) 13.23 (s, 1H), 8.98 (d, J = 2.2Hz, 1H), 8.17 (dd, J = 8.1, 2 .2Hz, 1H), 7.40 (d, J=8.1Hz, 1H), 2.83 (q, J=7.6Hz, 2H), 1.25 (t, J=7.6Hz, 3H).

[0419] 41A 3-(5-fluoropyridin-2-yl)-3-oxopropionic acid ethyl ester

[0420]

[0421] CDI (1.21 g, 7.44 mmol) was added to a solution of 5-fluoropyridine-2-carboxylic acid (1 g, 7.09 mmol) in THF (10 mL) and refluxed for 1 h. The reaction was cooled to rt, potassium 3-ethoxy-3-oxopropanoate (1.33 g, 7.80 mmol) was added, followed by MgCl (0.81 g, 8.50 mmol) and heated to 60 ° C overnight. Volatiles were removed under reduced pressure and the residue was distributed between sat.aq.NH4Cl (50 mL) and EtOAc (50 mL). The separated aqueous layer was extracted with EtOAc (50 mL), and the combined organics were dried (Na2SO4) and concentrated under reduced pressure. Purification by column chromatography (0-50% EtOAc in isohexane) gave a colorless oil (450 mg, 29%). LCMS (Method A) at 0.88 min m / z 166.3 [M-OCH2CH3] + (ES+). 1HNMR (500MHz, DMSO-d6) 8.73 (d, J=2.7Hz, 1H), 8.11 (dd, J=8.7, 4.7Hz, 1H), 7.99-7.91 (m, 1H), 4.16-4.00 (m, 4H), 1.14 (t, J=7.1Hz, 3H).

[0422] 42A 3-(2-methylpyridin-4-yl)-3-oxopropionic acid ethyl ester

[0423]

[0424] Potassium 3-ethoxy-3-oxopropanoate (2.05 g, 12.03 mmol) and NEt (4.57 mL, 32.81 mmol) were added to a cooling (0 °C) suspension of MgCl (1.25 g, 13.13 mmol) in MeCN (25 mL) and stirred for 3 h at rt (vial A). In a separate vial, CDI (1.86 g, 11.48 mmol) was added to a suspension of 2-methylpyridine-4-carboxylic acid (1.5 g, 10.94 mmol) in THF:MeCN (1:1; 20 mL) and stirred for 3 h at 40 °C (vial B). After this period of time, the contents of vial A were added to vial B via a pipette, and the combined reaction was stirred for 18 h at rt. The reaction mixture was poured into ice water (~10 mL), acidified to pH≈6 with concentrated HCl, and extracted with EtOAc (2×15 mL). The organics were washed with brine (50 mL), dried (MgSO4) and concentrated under reduced pressure to give a yellow oil (2.05 g, 90%) which was used without further purification. LCMS (Method F) m / z 208.3 [M+H]+ (ES+) at 0.88 min.

[0425] The following intermediates were prepared in a similar manner to Intermediate 42A.

[0426] Table 5 - Preparation Examples Prepared by General Ketoester Procedure

[0427]

[0428]

[0429]

[0430] 43A 2-Chloro-3-oxo-3-phenylpropionic acid ethyl ester

[0431]

[0432] Sulfuryl chloride (1.47mL, 18.19mmol) is added dropwise to a cooling (0°C) solution of ethyl 3-oxo-3-phenylpropionate (3mL, 17.32mmol) in CH Cl (65mL) and stirred for 3h at rt. The reaction is distributed between CH Cl (30mL) and saturated NaHCO aqueous solution (50mL). The separated aqueous layer is extracted with CH Cl (2×20mL), and the combined organic layer is washed with salt water (50mL), passed through a phase separation column, and concentrated under reduced pressure to obtain a yellow oil (3.93g, 80%). 1 HNMR (500MHz, CDCl3) 8.04-8.00 (m, 2H), 7.68-7.63 (m, 1H), 7.55-7.51 (m, 2H), 5.63 (s, 1H), 4.34-4.29 (m, 2H), 1.27 (t, J=7.1Hz, 3H).

[0433] 43B 2-Chloro-3-(2,4-difluorophenyl)-3-oxopropionic acid ethyl ester

[0434]

[0435] Prepared by a procedure analogous to that described for Intermediate 43A. 1 H NMR (500MHz, CDCl3) 8.07-8.00 (m, 1H), 7.08-7.03 (m, 1H), 6.96-6.91 (m, 1H), 5.60 (s, 1H), 4.32 (q, J=7.2, 0.7Hz, 2H), 1.30 (t, J=7.1Hz, 3H).

[0436] 44A 2-bromo-3-oxo-3-pyridin-3-ylpropionic acid ethyl ester

[0437]

[0438] Bromine (111 μL, 2.17 mmol) was added dropwise to a solution of ethyl 3-oxo-3-(3-pyridyl)propanoate (400 mg, 2.07 mmol) in CHCl (10 mL) and stirred at rt for 1 h. The reaction was diluted with CHCl (20 mL), washed with aq.NaS0 (10% w / v; 50 mL), sat.aq NaHCO (50 mL) and brine (50 mL), passed through a phase separation column and concentrated under reduced pressure to give an orange oil (501 mg, 62%) which was used without further purification. LCMS (Method A) m / z 272.2 / 274.2 [M+H] at 1.02 min + (ES+). 1H NMR(500MHz, CDCl3)9.23-9.19(m,1H),8.86-8.80(m,1H),8.32-8.28(m,1H),7.47(d dt, J=7.3, 4.7, 1.6Hz, 2H), 5.59 (s, 1H), 4.31 (q, J=7.2Hz, 2H), 1.28 (t, J=7.2Hz, 3H).

[0439] The following intermediates were prepared in a similar manner to Intermediate 44A.

[0440] Table 6 - Preparation Examples Prepared by General Bromination Procedure

[0441]

[0442]

[0443] 45A Ethyl 2-phenylimidazo[1,2-b]pyridazine-3-carboxylate

[0444]

[0445] A suspension of crude intermediate 43A (0.6 g, 1.85 mmol) and pyridazin-3-amine (0.18 g, 1.85 mmol) in EtOH (4 mL) was heated at 150 °C for 12 h by MWI. The reaction mixture was cooled to rt, evaporated under reduced pressure and the residue was purified by column chromatography (0-100% EtOAc in isohexane) to give a brown solid (147 mg, 29%). LCMS (Method E) m / z 268.3 [M+H] at 0.55 min + (ES+). 1 H NMR (500MHz, CDCl3) 8.60 (dd, J=4.5, 1.7Hz, 1H), 8.07 (dd, J=9.1, 1.7Hz, 1H), 7.86-7.79 (m, 2H ), 7.52-7.42 (m, 3H), 7.26 (dd, J=9.1, 4.5Hz, 1H), 4.42 (q, J=7.1Hz, 2H), 1.29 (t, J=7.2Hz, 3H).

[0446] The following intermediates were prepared in a similar manner to Intermediate 45A. Preparative Examples 45G to 45K were prepared from the corresponding crude 2-bromoketoester and 1.3 eq. of the corresponding pyridazin-3-amine.

[0447]

[0448]

[0449] 46A 6-methyl-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0450]

[0451] A solution of bromine (186 μL, 3.63 mmol) in CH2Cl2 (5 mL) was added dropwise to a cooled (0°C) solution of intermediate 42E (2.7 mL, 3.46 mmol) in CH2Cl2 (20 mL) and stirred overnight at rt. The reaction was diluted with CH2Cl2 (50 mL), washed with sat.aq NaHCO3 (100 mL), dried (Na2SO4) and concentrated under reduced pressure to give an orange oil (918 mg) which was used directly in the next step. The residue was dissolved in EtOH (3 mL), 6-methylpyridazine-3-amine (383 mg, 3.51 mmol) was added and the mixture was heated at 150°C by MWI. The reaction mixture was cooled to rt, evaporated under reduced pressure and the residue was purified by column chromatography (0-100% EtOAc in isohexane) to give an off-white solid (185 mg, 20%). LCMS (Method A) at 1.28 min m / z 351.3 [M+H] + (ES+). 1 H NMR (500MHz, DMSO-d6) 9.25 (d, J=2.0Hz, 1H), 9.08-9.03 (m, 1H), 8.60-8.55 (m, 1H), 8.25 (d, J =9.3Hz, 1H), 7.47 (d, J=9.4Hz, 1H), 4.30 (q, J=7.1Hz, 2H), 2.62 (s, 3H), 1.19 (t, J=7.1Hz, 3H).

[0452] The following intermediate was prepared in a similar manner to Intermediate 46A by MWI heating at 140 °C.

[0453]

[0454] 47A 6-methyl-2-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0455]

[0456] A solution of bromine (720 μL, 14.02 mmol) in CH2Cl2 (10 mL) was added dropwise to a cooled (0°C) solution of intermediate 42F (3.04 g, 13.35 mmol) in CH2Cl2 (40 mL) and stirred at rt for 2 h. The reaction was diluted with CH2Cl2 (50 mL), washed with saturated NaHCO3 aqueous solution (100 mL) and brine (100 mL), passed through a phase separation column, and concentrated under reduced pressure to give a yellow oil (4.15 g), which was used directly in the next reaction. The crude residue was dissolved in EtOH (15 mL), 6-methylpyridazine-3-amine (1.11 g, 10.15 mmol) was added and the mixture was heated at 140°C for 2.5 h by MWI. The reaction was cooled to rt, evaporated under reduced pressure and the residue was purified by column chromatography (0-10% MeOH in CH2Cl2) to give a yellow solid (2.24 g), which was used directly in the next reaction. The crude residue (200 mg) was dissolved in DMSO (6 mL) and treated with morpholine (0.07 mL, 0.85 mmol), followed by DIPEA (0.3 mL, 1.70 mmol), and stirred at rt for 18 h. Additional morpholine (0.07 mL, 0.85 mmol) and DIPEA (0.3 mL, 1.70 mmol) were added and the mixture was stirred for another 4 days at rt. The reaction was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with brine (3 × 20 mL), dried (MgSO ), and the solvent was removed under reduced pressure to obtain a light yellow solid (230 mg). LCMS (Method F) m / z 368.3 [M+H] + (ES +) at 0.42 min. 1H NMR (500MHz, CDCl3) δ8.69 (d, J=2.4Hz, 1H), 8.02 (dd, J=8.8, 2.4Hz, 1H), 7.91 (d, J=9.2Hz, 1H), 7.12 (d, J=9.2Hz, 1H), 6. 72 (d, J=8.8Hz, 1H), 4.44 (q, J=7.2Hz, 2H), 3.87 (t, J=4.9Hz, 4H), 3.65-3.60 (m, 4H), 2.70 (s, 3H), 1.37 (t, J=7.1Hz, 3H).

[0457] 48A 6-(azetidin-1-yl)-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0458]

[0459] A solution of intermediate 45D (72 mg, 0.230 mmol), azetidine (50 μL, 0.680 mmol), DIPEA (240 μL, 1.350 mmol) in DMSO (3 mL) was heated at 100 ° C for 18 h. The reaction mixture was cooled to rt, diluted with water (20 mL), and extracted with EtOAc (3×20 mL). The combined organics were washed with brine (50 mL), passed through a phase separation column and concentrated under reduced pressure to give an orange solid (68 mg, 85%), which was used without further purification. LCMS (Method E) m / z 341.4 [M+H] at 0.62 min + (ES+). 1 H NMR (500MHz, CDCl3) 7.77 (d, J=9.6Hz, 1H), 7.66 (td, J=7.4, 1.8Hz, 1H), 7.44-7.36 (m, 1H), 7.25 (td, J=7.5, 1.2Hz, 1H), 7.16 -7.10 (m, 1H), 6.57 (d, J=9.6Hz, 1H), 4.32 (q, J=7.2Hz, 2H), 4.21 (t, J=7.5Hz, 4H), 2.55-2.45 (m, 2H), 1.21 (t, J=7.1Hz, 3H).

[0460] The following intermediates were prepared in a similar manner to Intermediate 48A.

[0461]

[0462]

[0463] 48E 2-(2-Fluorophenyl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0464]

[0465] Prepared by a procedure similar to that described for Intermediate 48A with Intermediate 45D (162 mg, 0.42 mmol), 1-methylpiperazine (240 μL, 2.15 mmol) and DIPEA (240 μL, 1.35 mmol) in DMSO (5 mL). LCMS (Method B) m / z 384.4 [M+H] at 1.21 min + (ES+). 1H NMR (500MHz, CDCl3) 7.81 (d, J=9.9Hz, 1H), 7.65 (td, J=7.4, 1.8Hz, 1H), 7.43-7.38 (m, 1H), 7.25 (td, J=7.5, 1.1Hz, 1H), 7.13 (ddd, J=9.7, 8 .3, 1.2Hz, 1H), 7.01 (d, J=9.9Hz, 1H), 4.31 (q, J=7.2Hz, 2H), 3.67 (t, J=5.1Hz, 4H), 2.61-2.55 (m, 4H), 2.39 (s, 3H), 1.20 (t, J=7.1Hz, 3H).

[0466] 49A 6-(Ethylamino)-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0467]

[0468] A solution of Intermediate 45D (80 mg, 0.21 mmol), ethylamine (70% w / w in water; 68 μL, 0.85 mmol), DIPEA (296 μL, 1.70 mmol) in DMSO (6 mL) was heated at 100 °C for 18 h. Additional ethylamine (70% w / w in water; 1 mL, 17.97 mmol) was added and the reaction mixture was heated at 100 °C for an additional 2 h. The reaction mixture was cooled to rt, diluted with water (10 mL), and extracted with EtOAc (2×10 mL). The combined organics were washed with brine (20 mL), dried (MgSO4), and the solvent removed under reduced pressure to give an orange solid (74 mg, 85%) which was used without further purification. LCMS (Method B) m / z 329.4 [M+H] at 1.30 min + (ES+).

[0469] 50A 6-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0470]

[0471] A solution of Intermediate 45C (150 mg, 0.5 mmol), (1R, 4R)-2-oxa-5-azobicyclo[2.2.1]heptane chloride (81 mg, 0.6 mmol), DIPEA (296 μL, 1.7 mmol) in DMSO (2 mL) was heated at 100 °C overnight. The reaction mixture was cooled to rt, re-treated with additional (1R, 4R)-2-oxa-5-azobicyclo[2.2.1]heptane chloride (40 mg, 0.3 mmol) and DIPEA (113 μL, 0.646 mmol) and heated to 100 °C overnight. The reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine (3×40 mL), passed through a phase separation column, and concentrated under reduced pressure. Purification by column chromatography (0-100% EtOAc in isohexane) gave an off-white solid (86 mg, 46%). LCMS (Method A) m / z 365.3 [M+H] at 1.22 min + (ES+). 1 H NMR (500MHz, DMSO-d6) δ7.98 (d, J=9.8Hz, 1H), 7.76 (d, J=7.3Hz, 2H), 7.47-7.40 (m, 2 H), 7.40-7.35 (m, 1H), 7.14 (d, J=9.8Hz, 1H), 4.89 (s, 1H), 4.71 (s, 1H), 4.30 (q, J=7. 1Hz, 2H), 3.81 (d, J=7.5Hz, 1H), 3.75 (d, J=7.5Hz, 1H), 3.54 (d, J=10.2Hz, 1H), 3.40 ( d, J=10.2Hz, 1H), 1.98 (d, J=9.9Hz, 1H), 1.92 (d, J=9.9Hz, 1H), 1.25 (t, J=7.1Hz, 3H).

[0472] 51A 6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxylic acid ethyl ester

[0473]

[0474] A solution of intermediate 45C (175 mg, 0.58 mmol), (2S,5S)-1,2,5-trimethylpiperazine-1,4-diammonium dibromide (204 mg, 0.70 mmol), DIPEA (0.61 mL, 3.48 mmol) in DMSO (2 mL) was heated at 70 °C overnight. The reaction mixture was cooled to rt, treated with additional (1R,4R)-2-oxa-5-azobicyclo[2.2.1]heptane chloride (200 mg, 0.690 mmol) and DIPEA (0.61 mL, 3.480 mmol) and heated to 70 °C for the weekend. The reaction mixture was cooled to rt, diluted with brine (10 mL) and extracted with EtOAc (4×10 mL). The combined organic extracts were washed with brine (10 mL), passed through a phase separation column, and concentrated under reduced pressure to give an off-white solid (143 mg, 65%). LCMS (Method A) at 0.74 min m / z 378.4 [M+H] + (ES+). 1 H NMR (500MHz, DMSO-d6) 7.95 (d, J=9.8Hz, 1H), 7.79-7.73 (m, 2H), 7.46-7.41 (m, 2H), 7. 41-7.35 (m, 1H), 7.10 (d, J=9.8Hz, 1H), 4.65 (s, 1H), 4.30 (q, J=7.1Hz, 2H), 4.09 (q, J=5 .2Hz, 1H), 3.62-3.57 (m, 1H), 3.38 (d, J=10.1Hz, 1H), 3.17 (d, J=5.2Hz, 2H), 2.87 (d, J =9.6Hz, 1H), 2.33 (s, 2H), 1.95-1.92 (m, 1H), 1.85-1.79 (m, 1H), 1.25 (t, J = 7.1Hz, 3H).

[0475] 52A 2-(2-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0476]

[0477] A solution of intermediate 26B (190 mg, 0.635 mmol) and 5M aq.NaOH (0.635 mL, 3.174 mmol) in EtOH / water (3:1, 4 mL) was heated at 75 °C for 1 h. The reaction was cooled to rt and the EtOH was removed under reduced pressure. The residual aqueous solution was diluted with water (5 mL) and acidified with 1M HCl(aq) (pH≈1). The resulting precipitate was collected by filtration and purified by column chromatography (0-10% EtOH in EtOAc) to give a light yellow solid (128 mg, 74%). LRMS (APCI+) m / z 272.3 [M+H] +

[0478] 53A 2-(2,3-difluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0479]

[0480] A solution of intermediate 6O (129 mg, 0.425 mmol) and LiOH (1.5M aq; 2.83 mL, 4.25 mmol) in THF / MeOH (1:1; 4 mL) was stirred at 40°C overnight. The reaction was cooled to rt and washed with MTBE (3×10 mL). The aqueous layer was acidified (pH≈1) with 1M HCl(aq) and then extracted with CHCl3 / iPrOH (3:1; 3×10 mL). The combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure to give an orange solid (135 mg, 97%) which was used without further purification. LCMS (Method A) m / z 258.7 [M-OCH2CH3] at 0.89 min + . 1 H NMR (500MHz, DMSO-d6) 12.39 (s, 1H), 9.31 (dd, J=7.0, 1.8Hz, 1H), 8.85 (dd, J=4.2, 1.8Hz, 1H), 7.63-7.53 (m, 1H), 7.43-7.36 (m, 1H), 7.37-7.29 (m, 2H).

[0481] The following intermediate compounds were prepared by similar procedures as described for 53A.

[0482]

[0483]

[0484] 54A 2-(2-Fluoro-5-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0485]

[0486] A solution of intermediate 27F (334 mg, 0.855 mmol) and LiOH (1.5M aq; 2 mL, 3 mmol) in THF (9 mL) was heated at 40 °C overnight. Additional LiOH (1.5M aq; 2 mL, 3 mmol) and MeOH (2 mL) were added and the reaction was heated at 60 °C for 2 h. The reaction mixture was cooled to rt, diluted with water (20 mL) and washed with MTBE (2×25 mL). The aqueous layer was acidified (pH≈4) by dropwise addition of 1M aq.HCl and extracted with CHCl3 / iPrOH (3:1; 3×25 mL). The combined organic extracts were dried (Na2SO4) and the solvent was removed under reduced pressure to give an orange solid (200 mg, 70%). LCMS (Method A) m / z 273.6 [M+H] at 0.74 min + . 1 H NMR (500MHz, CDCl3) 12.27 (s, 1H), 9.30 (dd, J=7.0, 1.7Hz, 1H), 8.85 (dd, J=4.1, 1.8Hz , 1H), 8.18-8.14 (m, 1H), 7.98-7.92 (m, 1H), 7.33 (dd, J=7.0, 4.2Hz, 1H), 2.37 (s, 3H).

[0487] 55A 2-(2-Fluoro-5-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0488]

[0489] A mixture of Intermediate 2A (250 mg, 0.907 mmol), (2-fluoro-5-methylphenyl)boronic acid (172 mg, 1.117 mmol) and K2CO3 (432 mg, 2.721 mmol) in 1,4-dioxane:water (2:1, 3.0 mL) was sparged with N2 for 5 min. Pd(PPh3)4 (157 mg, 0.136 mmol) was added and the reaction was degassed with N2 for 5 min and then heated to 100 °C overnight. The reaction was cooled to rt and 2M aq.NaOH (3.0 mL) was added and then stirred at rt for 30 h. The mixture was concentrated under reduced pressure to remove 1,4-dioxane and then diluted with water (30 mL) and washed with MTBE (3×20 mL). The aqueous solution was acidified (pH≈2) with 1M aq.HCl and extracted with CHCl3 / iPrOH (3:1; 3×50 mL). The combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure to give a brown solid (238 mg, 74%). LCMS (Method A) m / z 294.0 [M+Na] at 0.94 min + . 1 H NMR (500MHz, DMSO-d6) 12.26 (s, 1H), 9.28 (dd, J=7.0, 1.8Hz, 1H), 8.83 (dd, J=4.2, 1.8Hz, 1H), 7.35 (m, 1H), 7.31 (m, 2H), 7.19 (m, 1H), 2.36 (s, 3H).

[0490] 56A 2-(2-Fluorophenyl)-6-(1-methylazetidin-3-yl)oxyimidazo[1,2-b]pyridazine-3-carboxylic acid

[0491]

[0492] NaH (60% dispersion in mineral oil, 31 mg, 0.774 mmol) was added to a cooled (0 °C) solution of 1-methylazetidin-3-ol hydrochloride (47 mg, 0.378 mmol) in DMF (4 mL) and stirred for 15 min. A solution of Intermediate 45D (55 mg, 0.172 mmol) in DMF (2 mL) was then added and the reaction was stirred at rt for 1 h. LiOH (103 mg, 4.301 mmol) was added and the solution was stirred for an additional 1 h. The reaction was acidified to pH ~4 with 1M aq. HCl, the volatiles were removed under reduced pressure and the residue was purified by reverse phase column chromatography (5-65% MeCN in 10 mM (NH4)2CO3 aqueous solution) to give an off-white solid (55 mg, 93%). LCMS (Method B) m / z 343.4 [M+H] at 0.47 min +(ES+).

[0493] 56B 2-(2-Fluorophenyl)-6-(2-methoxyethoxy)imidazo[1,2-b]pyridazine-3-carboxylic acid

[0494]

[0495] Prepared by a procedure analogous to that described for Intermediate 56A. LCMS (Method B) m / z 332.3 [M+H] at 0.49 min + (ES+).

[0496] 57A 6-(1-methylazetidin-3-yl)oxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxylic acid

[0497]

[0498] NaH (60% dispersion in mineral oil, 89 mg, 2.237 mmol) was added to a cooled (0 °C) solution of 1-methylazetidine-3-ol hydrochloride (135 mg, 1.094 mmol) in DMF (10 mL) and the mixture was stirred for 15 min. A solution of intermediate 45C (150 mg, 0.497 mmol) in DMF (2 mL) was added and the reaction mixture was warmed to rt and stirred for 2 h. A further suspension of NaH (89 mg, 2.237 mmol) and 1-methylazetidine-3-ol hydrochloride (135 mg, 1.094 mmol) in DMF (3 mL) was added, which had been stirred in a separate flask at rt for 45 min, and the reaction was stirred for an additional 1 h. LiOH (298 mg, 12.43 mmol) was added and the solution was stirred at rt for 72 h. The reaction was acidified to pH ˜4 with 1M aq. HCl, the volatiles were removed under reduced pressure and the residue was purified by reverse phase column chromatography (5-65% MeCN in 10 mM (NH 4 ) 2 CO 3 aqueous solution) to give a yellow solid (87 mg, 53%). LCMS (Method B) at 0.51 min m / z 324.6 [M+H] + (ES+).

[0499] 58A 2-(6-ethylpyridin-3-yl)-6-(trideuteromethoxy)imidazo[1,2-b]pyridazine-3-carboxylic acid

[0500]

[0501] LiOH (1.5 Maq; 0.49 mL, 0.736 mmol) was added to a solution of intermediate 46F (52 mg, 0.147 mmol) in methanol-d4 (1.2 mL, 29.5 mmol) and water (2 mL) and heated to 100 °C by MWI for 1 h. The reaction was cooled to rt, acidified to pH ~4 with 1M aq. HCl, and then concentrated under reduced pressure to give an off-white solid (40 mg, 86%), which was used without further purification. LCMS (Method A) had min m / z 301.7 [M+H] at 0.20 + (ES+).

[0502] Example

[0503] 1.2-[4-(Methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Step A)

[0504]

[0505] Intermediate 9B (122 mg, 0.450 mmol) was added to (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine -2-ketone (130 mg, 0.520 mmol), HATU (214 mg, 0.560 mmol) and NEt3 (0.200 mL, 1.430 mmol) in DMF (3 mL) was added and the mixture was stirred at rt overnight. The reaction was quenched with water (15 mL) and the resulting precipitate was filtered and washed with water (2×15 mL). The precipitate was dried under vacuum, dissolved with CH2Cl2 and purified by column chromatography (0-90% EtOAc in isohexane) to give a yellow solid (95 mg, 40%). LCMS (Method D) 502.29 [M+H]+ at 3.80 min. 1 H NMR (500MHz, DMSO-d6) 10.98 (s, 1H), 9.91 (d, J=7.8Hz, 1H), 9.31 (dd, J=6.9, 1.7Hz, 1H), 8.87 (dd, J=4.3, 1.7Hz, 1H), 7.81-7.74 (m, 2H), 7.6 8-7.42 (m, 6H), 7.37-7.32 (m, 2H), 7.31-7.24 (m, 2H), 6.58-6.51 (m, 2H), 5.98 (q, J=5.0Hz, 1H), 5.52 (d, J=7.8Hz, 1H), 2.71 (d, J=5.0Hz, 3H).

[0506] The compound was reacted with (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine by the amide coupling procedure A as described for the compound of Example 1. -2-one and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine The following compounds of the present invention were prepared by using the following oxazolidinones:

[0507] Table 3 - Example compounds prepared by amide coupling procedure A

[0508]

[0509]

[0510]

[0511]

[0512]

[0513]

[0514] 11.2-(1-methyl-2,3-dihydroindole-6-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Step B)

[0515]

[0516] LiOH (1.5M aq, 0.447 mL, 0.671 mmol) was added to a solution of intermediate 6E (12 mg, 0.038 mmol) in THF:MeOH (1:1, 4 mL) and the reaction mixture was stirred at 40 °C overnight. The mixture was cooled to rt, neutralized with HCl (1M aq, 0.671 mL, 0.671 mmol) and concentrated in vacuo. The crude product was dissolved in DMF (1.5 mL), NEt3 (11 μL, 0.076 mmol), HATU (22 mg, 0.057 mmol) and (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (13 mg, 0.052 mmol), and the reaction mixture was stirred at 40 ° C for 2 h. The reaction was quenched with water (10 mL), and the resulting precipitate was filtered and washed with water. The precipitate was purified by column chromatography (0 to 5% MeOH in CH2Cl2) to give a yellow solid (6 mg, 29%). LCMS (Method C) 528.30 [M+H] at 4.13 min + . 1 H NMR (500MHz, DMSO-d6) δ10.99 (s, 1H), 9.91 (d, J=7.8Hz, 1H), 9.33 (dd, J=6.9, 1.7Hz, 1H), 8.89 (dd, J=4.3, 1.7Hz, 1H), 7.72-7.63 (m, 3H), 7.56-7.42 (m, 5H), 7.38-7.23 (m, 4H), 6.52 (d, J=8.2Hz, 1H), 5.53 (d, J=7.8Hz, 1H), 3.36-3.26 (m, 2H), 2.92 (t, J=8.3Hz, 2H), 2.76 (s, 3H).

[0517] The following compounds of the invention were prepared via the amide coupling procedure B described for the compound of Example 11.

[0518] Table 4 - Compounds prepared by amide coupling step B

[0519]

[0520]

[0521]

[0522] 18. N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide

[0523]

[0524] Prepared from intermediate 14A by amide coupling procedure B as described for the compound of Example 11. LCMS (Method C) m / z 509.1 [M+H] at 3.88 min + . 1H NMR (500MHz, DMSO-d6) δ11.01 (s, 1H), 10.18 (d, J=7.6Hz, 1H), 8.98 (dd, J=4.6, 1.6Hz, 1H), 8.45 (dd, J=9.2, 1.6 Hz, 1H), 7.63-7.49 (m, 6H), 7.49-7.42 (m, 3H), 7.36-7.18 (m, 3H), 7.16 (d, J=7.9Hz, 1H), 5.57 (d, J=7.5Hz, 1H).

[0525] 19. N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide

[0526]

[0527] Prepared from intermediate 16A by amide coupling procedure A as described for the compound of Example 1, heating at 40°C overnight. LCMS (Method C) m / z 523.15 [M+H] at 4.12 min + . 1 H NMR (500MHz, DMSO-d6) δ11.01 (s, 1H), 10.59 (d, J = 7.2Hz, 1H), 8.33 (d, J = 9.3Hz, 1H), 7.63-7.41 (m , 9H), 7.36-7.28 (m, 1H), 7.28-7.20 (m, 2H), 7.20-7.14 (m, 1H), 5.53 (d, J=7.2Hz, 1H), 2.75 (s, 3H).

[0528] 20.6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-methylimidazo[1,2-b]pyridazine-3-carboxamide (Step C)

[0529]

[0530] HATU (205 mg, 0.540 mmol) was added to (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine under N2. -2-ketone (121mg, 0.45mmol), 6-chloro-2-methylimidazo [1,2-b] pyridazine-3-carboxylic acid (99.8mg, 0.47mmol) and DIPEA (172μL, 0.99mmol) in anhydrous DMF (2.88mL), and the reaction was stirred at rt for 24h. The reaction was quenched with water, and the resulting product was in the form of an off-white precipitate, which was filtered and washed with water. The precipitate was dissolved in EtOAc, and the solvent was removed under reduced pressure. Purification by column chromatography [10-37% (EtOH: CH2Cl2: NH4OH in CH2Cl2; 50:8:1)] gave a white solid (153mg, 74%). 1 H NMR (400MHz, DMSO-d6) δ11.03 (s, 1H), 9.91 (d, J = 7.1Hz, 1H), 8.36 (d, J = 9.5Hz, 1H), 7.69-7.57 (m, 2 H), 7.57-7.42 (m, 5H), 7.39-7.30 (m, 1H), 7.21 (d, J=7.9Hz, 1H), 5.60 (d, J=7.2Hz, 1H), 2.68 (s, 3H). LRMS(APCI+)m / z463.3[M+H] +

[0531] The following compounds were prepared by the amide coupling procedure C described above for the compound of Example 20. Examples 40 and 41 were prepared with additional purification by HPLC Method 1 (MeCN / water with 0.2% v / v formic acid; 25-100% over 18 min).

[0532] Table 5 - Example compounds prepared by amide coupling procedure C

[0533]

[0534]

[0535]

[0536]

[0537]

[0538] 42.2-(2,3-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Step D)

[0539]

[0540] NEt3 (59 μL, 0.423 mmol), HATU (79 mg, 0.206 mmol) and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (56 mg, 0.206 mmol) was added to a solution of intermediate 53A (57 mg, 0.206 mmol) in DMF (2 mL), and the reaction mixture was stirred at 40 ° C for 1 h. The reaction was quenched with water, and the resulting precipitate was filtered and washed with water (100 mL). The precipitate was dissolved in CH2Cl2 (30 mL), concentrated under reduced pressure, and purified by column chromatography (0 to 5% MeOH in CH2Cl2) to give an off-white solid (44 mg, 40%). LCMS (Method C) m / z 527.3 [M+H] at 4.39 min. + . 1 H NMR (500MHz, DMSO-d6) 10.97 (s, 1H), 9.61 (d, J=8.0Hz, 1H), 9.44 (dd, J=7.0, 1.7Hz, 1H), 9.02 (dd, J=4.3, 1.7Hz, 1H), 7.61-7.5 7 (m, 1H), 7.57-7.48 (m, 4H), 7.47-7.42 (m, 3H), 7.39-7.33 (m, 1H), 7.33-7.26 (m, 2H), 7.16-7.13 (m, 1H), 5.54 (d, J=7.9Hz, 1H).

[0541] The following compounds of the invention were prepared via the amide coupling procedure D described for the Example 42 compound.

[0542] Table 7 - Example compounds prepared by amide coupling procedure D

[0543]

[0544]

[0545]

[0546] 48.2-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (Step E)

[0547]

[0548] A solution of intermediate 33C (70 mg, 0.205 mmol) and LiOH (1.5M aq; 0.6 mL, 0.9 mmol) in THF / MeOH (1:1; 1 mL) was stirred at 40°C overnight. The mixture was cooled to rt, neutralized with 1M aq.HCl (0.92 mL, 0.920 mmol) and concentrated under reduced pressure. The crude residue was dissolved in DMF (1.26 mL), HATU (78 mg, 0.206 mmol), NEt3 (57 μL, 0.41 mmol) and then (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (41 mg, 0.205 mmol) was added and the reaction was stirred at 40°C overnight. Similar workup and purification as described for Example 42 gave a yellow solid (39 mg, 35%). LCMS (Method C) at 4.13 min m / z 547.3 [M+H] + . 1 H NMR (500MHz, DMSO-d6) 10.99 (s, 1H), 9.61 (d, J=8.0Hz, 1H), 9.38 (dd, J=7.0, 1.7Hz, 1H), 8.95(dd, J=4.3, 1.7Hz, 1H), 7.75-7.68(m, 1H), 7.68-7.61(m, 1H), 7.55-7.50(m, 1H), 7. 50-7.40(m, 4H), 7.40-7.35(m, 2H), 7.35-7.30(m, 2H), 7.30-7.23(m, 1H), 6.51(d, J=8.1 Hz, 1H), 5.47 (d, J=8.0Hz, 1H), 2.56-2.51 (m, 1H), 0.75-0.66 (m, 2H), 0.48-0.41 (m, 2H).

[0549] The following compounds of the invention were prepared by a similar procedure to that described for the compounds of Example 48 (amide coupling step E). The amide coupling step can be carried out at rt or 40°C and the stoichiometry of NEt3 employed can vary from 2 to 4 eq. For Examples 69-76, 10 eq. of LiOH (1.5 M aq.) was used in the ester hydrolysis stage. Example 75 was further purified by reverse phase column chromatography (15-65% MeCN in water w / 1% formic acid).

[0550] Table 8 - Examples prepared by amide coupling step E

[0551]

[0552]

[0553]

[0554]

[0555]

[0556]

[0557]

[0558]

[0559]

[0560]

[0561] 77.2-[6-(2-Hydroxy-2-methylpropyl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0562]

[0563] Prepared by amide coupling procedure E as described for the compound of Example 48, additional purification was performed by reverse phase column chromatography [5-40% MeCN (0.1% formic acid) in water (0.1% formic acid)], followed by preparative HPLC [Method 3: 15-100% MeCN in water (0.1% formic acid)] to give a white solid (9 mg, 5%). LCMS (Method C) m / z 564.4 [M+H] at 2.40 min + . 1 H NMR (500MHz, DMSO-d6) δ10.97 (s, 1H), 9.86 (d, J=7.8Hz, 1H), 9.43 (dd, J=7.0, 1.7Hz, 1H), 8.98 (dd, J=4.3, 1.7Hz, 1H), 8.89 (d, J=2.3Hz, 1H), 8.16 (dd, J=8. 1, 2.3Hz, 1H), 7.64-7.56(m, 1H), 7.56-7.49(m, 3H), 7.49-7.28(m, 5H), 7.18( d, J=7.9Hz, 1H), 5.59 (d, J=7.8Hz, 1H), 4.72 (s, 1H), 2.88 (s, 2H), 1.12 (s, 6H).

[0564] The following compounds of the invention were prepared by procedures analogous to those described for the compounds of Example 48 (Amide Coupling Step E). For Example 79, 10 eq. of LiOH (1.5 M aq.) was employed in the ester hydrolysis stage. Additional purification of Example 81 was performed by reverse phase column chromatography [15-70% MeCN in water w / 0.1% (NH4)2CO3].

[0565] Table 59 - Imidazolopyridazines prepared by amide coupling procedure E

[0566]

[0567]

[0568]

[0569] 84.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0570]

[0571] A solution of intermediate 6P (124 mg, 0.282 mmol) and LiOH (1.5M aq; 0.55 mL, 0.825 mmol) in THF / MeOH (1:1; 2.18 mL) was stirred at rt overnight and then at 40 °C for 86 h. The mixture was cooled to rt, acidified (pH≈1) with 1 Maq.HCl (0.92 mL, 0.920 mmol) and concentrated under reduced pressure. A portion of the crude acid (52 mg, 0.135 mmol) was used directly in the next reaction and dissolved in DMF (1.5 mL). HATU (51 mg, 0.135 mmol), NEt3 (75 μL, 0.541 mmol) and then (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (36 mg, 0.135 mmol) and the reaction was stirred at rt for 1 h. The reaction was quenched with water (5 mL), acidified with AcOH (pH ≈ 2), and purified by ion exchange chromatography (2 g SCX-2). The resulting residue was further purified by column chromatography [0-7% (0.7N NH3 in MeOH) in CH2Cl2] to give a cream solid (13 mg, 15%) as a mixture of rotamers. 0.5H corresponds to 11H of one rotamer peak in H NMR assignment. LCMS (Method C) at 2.42 min m / z 619.4 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.08-10.89 (m, 1H), 10.02-9.92 (m, 1H), 8.85-8.75 (m, 1H), 7.61-7.54 (m, 1H), 7.54-7.39 (m, 6H) , 7.34-7.25 (m, 1H), 7.24-7.10 (m, 3H), 6.85 (d, J=7.8Hz, 0.5H), 6.54 (d, J=7.8Hz, 0.5H), 5.49-5.43 (m, 1H), 5.40 (d, J=7. 3Hz, 0.5H), 4.82 (s, 0.5H), 4.16-4.09 (m, 0.5H), 3.68-3.60 (m, 0.5H), 3.58 (s, 0.5H), 3.52-3.43 (m, 1.5H), 2.95-2.87 (m, 0.5H), 2.84-2.77(m, 0.5H), 2.70-2.63(m, 0.5H), 2.37-2.27(m, 3H), 2.01-1.94(m, 0.5H), 1.93-1.79(m, 2H), 1.75(s, 1H).

[0572] 85.2-(2-Fluoro-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0573]

[0574] 86.2-(2-Methoxy-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0575]

[0576] A solution of intermediate 27B (227 mg, 0.717 mmol) and LiOH (1.5M aq; 4.78 mL, 7.17 mmol) in THF / MeOH (1:1; 6 mL) was heated at 40°C for 48 h. The reaction mixture was cooled to rt, diluted with water (20 mL) and washed with MTBE (3×10 mL). The aqueous layer was acidified (pH≈1) with 1M aq.HCl and extracted with CHCl3 / iPrOH (3:1; 3×10 mL). The combined organic extracts were dried (Na2SO4) and the solvent removed under reduced pressure to give a white solid (151 mg) which was used without further purification. The residue was dissolved in DMF (1.5 mL), HATU (208 mg, 0.547 mmol), NEt3 (123 μL, 0.882 mmol) and then (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-one (137 mg, 0.546 mmol) was added and the reaction was stirred at 40° C. for 1 h. Workup and purification similar to that described for Example 42 was performed, followed by additional purification by preparative HPLC [Method 2: 20-100% MeCN in water (0.1% formic acid)].

[0577] Example 85: White solid (28 mg, 8%). LCMS (Method C) 506.4 [M+H]+ at 3.73 min. 1 H NMR (500MHz, DMSO-d6) δ11.01 (s, 1H), 9.56 (d, J=8.0Hz, 1H), 9.43 (dd, J=7.0, 1.7Hz, 1H), 9.01 (dd, J=4.3, 1.7Hz, 1H), 7.96 (dd, J =9.6, 7.5Hz, 1H), 7.68-7.61 (m, 1H), 7.54-7.48 (m, 1H), 7.48-7.40 (m, 5H), 7.34-7.23 (m, 4H), 5.45 (d, J = 8.0Hz, 1H), 2.47 (s, 3H).

[0578] Example 86: White solid (14 mg, 3%). LCMS (Method C) at 3.96 min m / z 518.5 [M+H] + . 1HNMR (500MHz, DMSO-d6) δ10.99 (s, 1H), 9.50 (d, J=8.0Hz, 1H), 9.37 (dd, J=7.0, 1.7H z, 1H), 8.95 (dd, J=4.3, 1.7Hz, 1H), 7.67-7.61 (m, 1H), 7.59 (d, J=7.4Hz, 1H), 7.53-7 .48(m, 1H), 7.48-7.41(m, 4H), 7.37(dd, J=7.0, 4.3Hz, 1H), 7.34-7.28(m, 2H), 7.28- 7.22 (m, 1H), 6.89 (d, J=7.4Hz, 1H), 5.41 (d, J=7.9Hz, 1H), 3.74 (s, 3H), 2.43 (s, 3H).

[0579] 87.N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide (Step F)

[0580]

[0581] A solution of intermediate 45A (58 mg, 0.217 mmol) and LiOH·H2O (91 mg, 2.174 mmol) in MeOH:THF:water (2:2:1; 5 mL) was heated to 50°C for 2 h. The reaction mixture was cooled to rt, neutralized with 1M aq.HCl to pH≈7, and then concentrated under reduced pressure. The crude product was dissolved in DMF (1.5 mL) and (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (55 mg, 0.217 mmol) and NEt3 (91 μL, 0.651 mmol) were added, followed by HATU (83 mg, 0.217 mmol). The reaction was stirred at rt for 18 h, quenched with water (10 mL), and the resulting precipitate was filtered and washed with water. The precipitate was dissolved in 10% MeOH / CH2Cl2, passed through a phase separation column, concentrated under reduced pressure, and purified by column chromatography (0-10% MeOH in CH2Cl2) to give an off-white solid (30 mg, 29%). LCMS (Method D) m / z 473.4 [M+H] at 3.89 min + . 1H NMR (500MHz, DMSO-d6) δ11.05 (s, 1H), 10.34 (d, J=7.4Hz, 1H), 8.86 (dd, J=4.5, 1.6Hz, 1H), 8.38 (dd, J=9.2, 1.6Hz, 1H), 8.01-7.95 (m, 2H), 7.68 (ddd, J=8.6, 7.2, 1.6Hz, 1H), 7.57-7.39 (m, 9H), 7.36 (dd, J=8.1, 1.4Hz, 2H), 7.29 (ddd, J=8.3, 7.3, 1.2Hz, 1H), 5.54 (d, J=7.4Hz, 1H).

[0582] The following compounds of the invention were prepared by the amide coupling procedure F as described for the compound of Example 87. This step was performed with 5 eq. of NEt3 for Examples 95-105 and 10 eq. of NEt3 for Example 106. Additional purification of Example 107 was performed by reverse phase column chromatography (5-60% MeCN in 10 mM (NH4)2CO3 aq. solution).

[0583] Table 610 - Example compounds prepared by amide coupling procedure F

[0584]

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591] 108.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(1-methylazetidin-3-yl)oxyimidazo[1,2-b]pyridazine-3-carboxamide

[0592]

[0593] HATU (61 mg, 0.161 mmol) was added to the crude Intermediate 56A (55 mg, 0.161 mmol), (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine -2-ketone (43 mg, 0.161 mmol) and NEt3 (112 μL, 0.803 mmol) in DMF (3 mL) was added and the reaction was stirred overnight at rt. Similar workup and purification as described for the compound of Example 87 gave an off-white solid (30 mg, 31%). LCMS (Method D) at 3.85 min m / z 594.4 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.08 (s, 1H), 9.89 (d, J = 7.5Hz, 1H), 8.33 (d, J = 9.7Hz, 1H), 7.65-7.41 (m, 8H), 7.37-7.16 (m, 5H), 5.55 (d, J=7.5Hz, 1H), 5.51 (p, J=5.4Hz, 1H), 3.92 (t, J=7.1Hz, 1H), 3.85 (t, J=7.2Hz, 1H), 3.27-3.19 (m, 2H), 2.22 (s, 3H).

[0594] 109.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-(1-methylazetidin-3-yl)oxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0595]

[0596] Prepared by a procedure analogous to that described for the compound of Example 108. LCMS (Method D) m / z 576.4 [M+H] at 4.05 min + . 1H NMR (500MHz, DMSO-d6) δ11.07 (s, 1H), 10.01 (d, J = 7.3Hz, 1H), 8.29 (d, J = 9.7Hz, 1H), 7. 93-7.84 (m, 2H), 7.63 (ddd, J=9.9, 8.2, 1.4Hz, 1H), 7.60-7.52 (m, 3H), 7.51-7.44 (m, 2H) , 7.43-7.31 (m, 4H), 7.22 (dd, J=9.4, 7.8Hz, 2H), 5.62 (d, J=7.3Hz, 1H), 5.45 (p, J=5.4Hz , 1H), 3.91 (t, J=7.1Hz, 1H), 3.85 (t, J=7.4Hz, 1H), 3.22 (d, J=15.4Hz, 2H), 2.23 (s, 3H).

[0597] 110.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(2-methoxyethoxy)imidazo[1,2-b]pyridazine-3-carboxamide

[0598]

[0599] Prepared by a procedure analogous to that described for the compound of Example 108 using 10 eq NEt3 at the amide coupling stage and additional purification by reverse phase column chromatography [10-60% MeCN in 10 mM (NH4)2CO3 aq. solution]. LCMS (Method D) m / z 582.6 [M+H] at 4.20 min + . 1 H NMR (500MHz, DMSO-d6) δ11.09 (s, 1H), 10.23 (d, J=7.2Hz, 1H), 8.31 (d, J=9.7Hz, 1H), 7.59 (t, J= 9.2Hz, 1H), 7.56-7.41 (m, 7H), 7.33 (t, J=7.0Hz, 1H), 7.29 (d, J=9.8Hz, 1H), 7.25 (td, J=7.5, 1.1 Hz, 1H), 7.23-7.18 (m, 1H), 7.17 (d, J=7.9Hz, 1H), 5.52 (d, J=7.1Hz, 1H), 4.84 (ddd, J=12.0, 5.8 , 3.1Hz, 1H), 4.71 (ddd, J=12.0, 5.4, 3.0Hz, 1H), 3.78 (ddd, J=7.1, 4.5, 3.1Hz, 2H), 3.33 (s, 3H).

[0600] 111.6-Methoxy-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide

[0601]

[0602] LiOH (1.5M aq; 1.75 mL, 2.625 mmol) was added to a solution of intermediate 45C (180 mg, 0.597 mmol) in MeOH:water (1:1; 4 mL) and heated to 100 °C by MWI for 1 h. The reaction was cooled to rt, acidified with 1M aq.HCl (3 mL), and then concentrated under reduced pressure to give an off-white solid (161 mg), which was used directly in the next reaction. A portion of the crude residue (80 mg, 0.297 mmol) was dissolved in DMF (1.8 mL), HATU (113 mg, 0.298 mmol), NEt3 (124 μL, 0.891 mmol) and (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (75 mg, 0.297 mmol) was added and the reaction mixture was stirred at 40°C overnight. Similar workup and purification as described for Example 42 gave a white solid (32 mg, 22%). LCMS (Method C) m / z 503.4 [M+H] at 4.32 min + . 1 H NMR (500MHz, DMSO-d6) δ11.06 (s, 1H), 10.36 (d, J=7.2Hz, 1H), 8.26 (d, J=9.7Hz, 1H), 7.92-7.86 (m, 2H), 7.70- 7.63 (m, 1H), 7.55-7.32 (m, 10H), 7.32-7.25 (m, 1H), 7.22 (d, J=9.7Hz, 1H), 5.51 (d, J=7.1Hz, 1H), 4.21 (s, 3H).

[0603] The following compounds of the invention were prepared by similar procedures as described for the compound of Example 111 with additional purification of Examples 113 and 114 by reverse phase column chromatography (10-65% MeCN in water w / 0.1% formic acid).

[0604]

[0605]

[0606] 115.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methoxyimidazo[1,2-b]pyridazine-3-carboxamide

[0607]

[0608] A solution of intermediate 45D (45 mg, 0.141 mmol) and LiOH.H2O (59 mg, 1.41 mmol) in MeOH:THF:water (2:2:1; 5 mL) was heated at 50 °C for 18 h. The reaction was cooled to rt, acidified to pH≈4 with 1M aq.HCl and the solvent removed under reduced pressure. The crude residue was dissolved in DMF (1.5 mL), (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added -2-ketone (40 mg, 0.141 mmol) and NEt3 (39 μL, 0.281 mmol) were added followed by HATU (54 mg, 0.141 mmol). The reaction was stirred at rt for 3 h. Workup and purification similar to that described for Example 42 followed by additional purification by reverse phase column chromatography [5-75% MeCN in 10 mM (NH4)2CO3 aq. solution] gave an off-white solid (18 mg, 23%). LCMS (Method C) m / z 539.4 [M+H] at 4.13 min. + . 1 H NMR (500MHz, DMSO-d6) δ11.04 (s, 1H), 10.30 (d, J=7.2Hz, 1H), 8.31 (d, J=9.7Hz, 1H), 7.60 (t, 1H), 7. 55-7.42 (m, 7H), 7.32 (td, J=8.0, 4.9Hz, 1H), 7.29-7.15 (m, 4H), 5.54 (d, J=7.2Hz, 1H), 4.24 (s, 3H).

[0609] 116.6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide

[0610]

[0611] A solution of intermediate 45D (45 mg, 0.141 mmol) and LiOH.H2O (59 mg, 1.41 mmol) in THF:water (2:1; 3 mL) was heated to 50 °C for 3 h. The reaction mixture was cooled to rt, neutralized with 1M aq.HCl to pH≈7, and then concentrated under reduced pressure. The crude residue was dissolved in DMF (3 mL) and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (38 mg, 0.141 mmol) and NEt3 (20 μL, 0.141 mmol) were added, then HATU (54 mg, 0.141 mmol) was added, and the reaction was stirred at rt for 18 h. Workup and purification were performed similarly to that described for Example 42, followed by purification by reverse phase column chromatography (10 mM (NH4)2CO3 aq. solution 15-75% MeCN] to give an off-white solid (13 mg, 17%). LCMS (Method D) at 4.18 min m / z 543.4 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.01 (s, 1H), 9.92 (d, J = 7.4Hz, 1H), 8.50 (d, J = 9.5Hz, 1H), 7.73 (d, J = 9.5Hz, 1H ), 7.65-7.58 (m, 2H), 7.58-7.44 (m, 6H), 7.37-7.22 (m, 3H), 7.18 (d, J=7.7Hz, 1H), 5.54 (d, J=7.3Hz, 1H).

[0612] 117.6-Chloro-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0613]

[0614] A solution of intermediate 46F (63 mg, 0.179 mmol) and 1.5M aq.LiOH (0.359 mL, 0.538 mmol) in THF (3 mL) was stirred overnight at rt. The reaction mixture was acidified to pH ≈ 4 with 1M aq.HCl and then concentrated under reduced pressure. The crude residue was dissolved in DMF (1.8 mL) and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (48 mg, 0.179 mmol) and NEt3 (75 μL, 0.538 mmol) were added, then HATU (68 mg, 0.179 mmol) was added, and the reaction was stirred at rt for 30 min. Similar workup and purification as described for Example 42 gave a beige solid (50 mg, 48%). LCMS (Method C) at 2.77 min m / z 554.4 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.04-11.00 (m, 1H), 10.18 (d, J=7.2Hz, 1H), 9.05-9.00 (m , 1H), 8.46 (d, J=9.5Hz, 1H), 8.26 (dd, J=8.1, 2.3Hz, 1H), 7.67 (d, J=9.5Hz, 1H), 7.6 6-7.60 (m, 1H), 7.59-7.53 (m, 3H), 7.48 (t, J=7.4Hz, 2H), 7.39-7.31 (m, 2H), 7.21 (d , J=7.9Hz, 1H), 5.61 (d, J=7.2Hz, 1H), 2.82 (q, J=7.6Hz, 2H), 1.28 (t, J=7.6Hz, 3H).

[0615] 118.N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-(5-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide

[0616]

[0617] A solution of intermediate 46C (130 mg, 0.308 mmol) and LiOH (74 mg, 3.083 mmol) in MeOH:THF:water (4:3:3; 10 mL) was heated at 50 °C for 1 h. The reaction was cooled to rt, acidified to pH≈4 with 1M aq.HCl and the solvent removed under reduced pressure. The crude residue was dissolved in DMF (6 mL) and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (83 mg, 0.308 mmol) and NEt3 (214 μL, 1.539 mmol) were added, then HATU (117 mg, 0.308 mmol) was added, and the reaction was stirred at rt for 1 h. Workup and purification similar to that described for Example 87 gave a yellow solid (40 mg, 24%). LCMS (Method C) at 2.63 min m / z 536.4 [M+H] + .1 H NMR (500MHz, DMSO-d6) δ11.06 (s, 1H), 10.42 (d, J=7.1Hz, 1H), 8.81 (d, J=2.0Hz , 1H), 8.41 (s, 1H), 8.30 (d, J=9.7Hz, 1H), 8.05 (s, 1H), 7.61 (t, J=9.3Hz, 1H), 7 .54-7.49 (m, 3H), 7.45 (t, J=7.5Hz, 2H), 7.33 (d, J=5.9Hz, 1H), 7.26 (d, J=9.7H z, 1H), 7.19 (d, J=8.0Hz, 1H), 5.60 (d, J=6.9Hz, 1H), 4.23 (s, 3H), 2.35 (s, 3H).

[0618] The following compounds of the invention were prepared by procedures similar to those described for the compound of Example 118.

[0619]

[0620]

[0621] 121.2-(6-ethylpyridin-3-yl)-6-methoxy-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0622]

[0623] LiOH (1.5M aq; 0.643 mL, 0.965 mmol) was added to a solution of intermediate 46F (68 mg, 0.193 mmol) in THF:MeOH (1:1; 4 mL) and stirred at rt for 4 days. The reaction was then acidified to pH≈4 with 1M aq.HCl and concentrated under reduced pressure to give an off-white solid (123 mg) which was used directly in the next reaction. A portion of the crude residue (58 mg, 0.193 mmol) was dissolved in DMF (1.5 mL), NEt3 (81 μL, 0.579 mmol) and (3S)-3-amino-5-phenyl-1,3-dihydro-1,4-benzodiazepine were added. -2-ketone (53 mg, 0.196 mmol) was then added HATU (74 mg, 0.195 mmol) and the reaction mixture was stirred at rt for 1 h. The reaction was quenched with water (15 mL) and the resulting precipitate was filtered and washed with water (2×15 mL). The precipitate was dissolved in CH2Cl2, concentrated under reduced pressure, and purified by column chromatography (0 to 5% MeOH in CH2Cl2). Further purification by preparative HPLC method 4 [20-100% MeCN in water (0.1% formic acid)] gave a white solid (9.7 mg, 9%). LCMS (Method C) m / z 550.1 [M+H] at 1.02 min + . 1 H NMR (500MHz, DMSO-d6) δ11.05 (s, 1H), 10.42 (d, J=7.0Hz, 1H), 8.93-8.88 (m, 1H), 8.31 (d , J=9.7Hz, 1H), 8.14 (dd, J=8.1, 2.3Hz, 1H), 7.66-7.58 (m, 1H), 7.56-7.49 (m, 3H), 7.48- 7.43 (m, 2H), 7.37-7.32 (m, 1H), 7.30 (d, J=8.1Hz, 1H), 7.26 (d, J=9.7Hz, 1H), 7.22-7.17 (m, 1H), 5.60 (d, J=7.1Hz, 1H), 4.24 (s, 3H), 2.79 (q, J=7.6Hz, 2H), 1.26 (t, J=7.6Hz, 3H).

[0624] 122.6-Ethoxy-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide

[0625]

[0626] A solution of intermediate 46F (60 mg, 0.172 mmol) and 1.5M aq of LiOH (0.572 mL, 0.858 mmol) in EtOH:THF (1:1; 4 mL) was heated at 50 °C for 1 h. The reaction was cooled to rt, acidified to pH≈4 with 1M aq.HCl and the solvent removed under reduced pressure. The crude residue was dissolved in DMF (1.5 mL) and (3S)-3-amino-9-fluoro-5-phenyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (46 mg, 0.172 mmol) and NEt3 (72 μL, 0.515 mmol) were added, followed by HATU (68 mg, 0.178 mmol) and the reaction was stirred at rt for 1.5 h. The reaction was diluted with EtOAc (50 mL), washed with brine (3×50 mL), dried (Na2SO4) and the solvent removed under reduced pressure. The residue was purified by column chromatography (0-3% MeOH in CH2Cl2) and reverse phase column chromatography [35-65% MeCN (0.1% formic acid) in water (0.1% formic acid)]. The obtained material was dissolved in CHCl3 / iPrOH (3:1; 25 mL), washed with saturated aqueous NaHCO3 (2×20 mL) and dried (Na2SO4) to give a white solid (17 mg, 18%). LCMS (Method C) m / z 540.3 [M+H] at 3.63 min + . 1 H NMR (500MHz, DMSO-d6) δ11.07 (s, 1H), 10.30 (d, J=7.2Hz, 1H), 8.63-8.59 (m, 1H), 8.53-8.48 (m, 1H), 8.34 (d, J=9.8Hz, 1H), 7.64- 7.57 (m, 2H), 7.57-7.50 (m, 1H), 7.52-7.42 (m, 4H), 7.37-7.28 (m, 2H), 7.17 (d, J=7.9Hz, 1H), 5.54 (d, J=7.1Hz, 1H), 4.25 (s, 3H).

[0627] 123.2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-6-(2H3)methoxyimidazo[1,2-b]pyridazine-3-carboxamide

[0628]

[0629] Prepared by amide coupling procedure A as described for the compound of Example 1. LCMS (Method C) m / z 553.4 [M+H] at 2.72 min + . 1H NMR (500MHz, DMSO-d6) δ11.05 (s, 1H), 10.41 (d, J=7.1Hz, 1H), 8.92-8.87 (m, 1H), 8.30 (d, J=9.7Hz, 1H), 8.14 (dd, J=8.1, 2.3Hz, 1H), 7.65-7.57 (m, 1H), 7.55-7.48 (m, 3H), 7 .47-7.42(m, 2H), 7.36-7.31(m, 1H), 7.30(d, J=8.1Hz, 1H), 7.25(d, J=9.7Hz, 1H), 7.1 9 (d, J=7.9Hz, 1H), 5.59 (d, J=7.1Hz, 1H), 2.78 (q, J=7.6Hz, 2H), 1.25 (t, J=7.6Hz, 3H).

[0630] 124.2-(6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0631]

[0632] Example 67 (40 mg) was purified by preparative chiral HPLC [70% MeCN in water (0.1% ammonia)] to afford the title compound as a single diastereomer of unknown absolute configuration with the arbitrarily defined stereocenter marked by an asterisk. Secondary eluting enantiomer. Yellow solid (12 mg, 30%). Analytical chiral HPLC: 8.99 min. LCMS (Method D) 573.4 [M+H] at 3.95 min. + . 1H NMR (500MHz, DMSO-d6) δ11.00 (s, 1H), 9.87 (d, J=7.8Hz, 1H), 9.38 (dd, J=7.0, 1.7Hz, 1H), 8.93 (dd, J=4.3, 1.7Hz, 1H), 8.66 (d, J=2.3Hz, 1H), 8.09 (dd, J=8.9, 2.4Hz, 1H), 7.70-7.63 (m, 1H), 7.56-7.41 (m, 5H), 7.39-7.32 (m, 3H), 7.32-7.25 (m, 1H), 6.80 (d, J=9.0Hz, 1H), 5.52 (d, J=7.8Hz, 1H), 4.42-4.36 (m, 1H), 3.98-3.91 (m, 2H), 3.73 (d, J= 11.3Hz, 1H), 3.63 (dd, J=11.3, 3.1Hz, 1H), 3.48 (td, J=11.3, 3.1Hz, 1H), 3.15-3.05 (m, 1H), 1.15 (d, J=6.7Hz, 3H).

[0633] 125. N-[(3S)-9-Fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-2-{6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl}pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0634]

[0635] Example 68 (40 mg) was purified by preparative chiral SFC [50% MeOE:MeCN (1:1) w / 0.1% ammonia] to afford the title compound as a single diastereomer of unknown absolute configuration with the arbitrarily defined stereocenter marked by an asterisk. Second eluting enantiomer. Yellow solid (3.8 mg, 9%). Analytical SFC: 7.86 min. LCMS (Method D) m / z 591.5 [M+H] at 3.94 min. + . 1H NMR (500MHz, DMSO-d6) δ9.88 (d, J=7.8Hz, 1H), 9.38 (dd, J=7.0, 1.7Hz, 1H), 8.93 (dd, J=4.3, 1.7Hz, 1H), 8.66 (d, J=2.3Hz, 1H), 8.09 (dd, J=8.9, 2.3Hz, 1H), 7.65-7.58 (m, 1H), 7.57-7.50 (m, 3H), 7.50-7.41 (m, 2H), 7.39- 7.30 (m, 2H), 7.19 (d, J=7.9Hz, 1H), 6.80 (d, J=8.9Hz, 1H), 5.60 (d, J=7.7Hz, 1H), 4.42-4.36 (m, 1H), 3.98-3. 92 (m, 2H), 3.76-3.70 (m, 1H), 3.67-3.60 (m, 1H), 3.52-3.43 (m, 1H), 3.15-3.05 (m, 1H), 1.15 (d, J=6.7Hz, 3H).

[0636] Example 127: In vitro efficacy

[0637] Compounds were subjected to RSV plaque reduction assay according to the following protocol. Plaque EC 50 and cytotoxic CC 50 Values ​​are the means of at least two experiments, and numbers are rounded to integers.

[0638] Plaque reduction assay

[0639] Hep-G2 cells (ECACC, 85011430) are passaged in flasks and inoculated in 24-well plates containing antibiotics and being supplemented with the DMEM of 10%FBS. During inoculation and subsequent culture, cells are cultivated in the DMEM containing 2%FBS. The RSV (RSV A2 ECACC, 0709161v) of 100 plaque forming units / well is mixed with eight kinds of serial dilutions of compound. Subsequently, the virus / compound mixture of 100 μL is added in the Hep-G2 cell monolayer that converges. Cell and virus / compound mixture are cultivated 2h in incubator at 37 ℃ in humidified 5%CO, then remove inoculum and add 1mL to contain the covering material (DMEM containing 2%FBS and 0.8%CMC) of compound dilution. At 37 ℃ in humidified 5%CO, culture cells 2 days in incubator.

[0640] Wash the cells with PBS for 3 min before adding 75 / 25% v / v EtOH / MeOH. Remove the fixative and wash the plate with PBS. Add a pre-titrated amount of primary antibody in 200 μL PBS / 2% milk powder and incubate the plate at 37°C for 90 min. Wash the plate 3 times with PBS / 0.05% Tween20, then add 200 μL rabbit anti-goat horseradish peroxidase in PBS / 2% milk powder and incubate at 37°C for 1 h. After three washing steps with PBS / 0.05% Tween20, add 200 μL ready-to-use TrueBlue and incubate the plate at rt for 10-15 min, then wash with water. After removing the water, air dry the plate in the dark.

[0641] The plates were scanned and analyzed using an Immunospot S6 Macro analyzer equipped with BioSpot analysis software for counting immunostained plaques (virus plaques). Plaque counts were used to calculate the percentage of infection of RSV relative to the average of plaque counts in virus control wells. The EC was calculated by interpolating inhibition curves fitted with a 4-parameter nonlinear regression with variable slopes in Dotmatics. 50 Values ​​were calculated as 50% reduction in signal. 50 and cytotoxic CC 50 Values ​​are means of at least two experiments, and numbers are rounded to integers.

[0642] result

[0643]

[0644]

[0645]

[0646]

[0647]

[0648] Example 128: Thermodynamic Solubility

[0649] The test compound (2.5 mg solid; n = 1) was weighed in an amber glass vial, and a buffer (0.5 mL) (usually phosphate buffered saline at pH 7.4) was added. The solution was stirred overnight at ambient temperature using a vial roller system. The solution was then filtered (0.45 μm pore size; no pre-saturation). Repeated aliquots (50 μL) were sampled from the filtrate and diluted with a volume of Milli-Q water and methanol (1: 1 v / v) before analysis by HPLC-UV. A standard of 10 mg / mL (n = 1) was prepared in DMSO and then diluted 10 times in Milli-Q water and methanol (1: 1 v / v) to obtain a 1 mg / mL solution. The concentration of the test compound in the filtrate was quantified relative to the concentration standard. A gradient HPLC-MS system was used for analysis.

[0650] result

[0651] Example Thermodynamic solubility (μM) 20 3.84 21 4.64

[0652] Example 129: In vitro pharmacokinetics

[0653] Compounds were subjected to the following assays to study liver microsomal stability and hepatocyte stability.

[0654] Microsome Culture: Protocol

[0655] Pooled liver microsomes were purchased from a reputable commercial supplier and stored at -80°C before use. Microsomes (final protein concentration 0.5 mg / mL), 0.1 M phosphate buffer pH 7.4 and test compounds (final substrate concentration 1 μM; final DMSO concentration 0.25%) were pre-cultured at 37°C, and then NADPH (final concentration 1 mM) was added to start the reaction. The final culture volume was 50 μL. Control cultures were included for each test compound in the presence of 0.1 M phosphate buffer pH 7.4 instead of NADPH (minus NADPH). Two control compounds were included for each species. All cultures were performed separately for each test compound. Each compound was cultured for 0, 5, 15, 30 and 45 min. The control (minus NADPH) was cultured only for 45 min. At the appropriate time point, the reaction was stopped by transferring the culture to acetonitrile at a ratio of 1:3. The termination plate was centrifuged at 3,000 rpm for 20 min at 4°C to precipitate the protein. After protein precipitation, the sample supernatants were combined into a box of up to 4 compounds, internal standards were added, and the samples were analyzed by LC-MS / MS. From the plot of ln peak area ratio (compound peak area / internal standard peak area) versus time, the gradient of the line was determined. Subsequently, the half-life (t 1 / 2 ) and intrinsic clearance (CL intCompounds with low clearance (>80% retention at 45 min) under the assay conditions are denoted as t 1 / 2 >140min.

[0656] result

[0657]

[0658]

[0659]

[0660] Hepatocyte culture: experimental procedures

[0661] Cryopreserved pooled hepatocytes were purchased from a reputable commercial supplier and stored in liquid nitrogen before use. Williams E medium supplemented with 2 mM L-glutamine and 25 mM HEPES and the test compound (final substrate concentration 3 μM; final DMSO concentration 0.25%) were pre-incubated at 37°C, and then a suspension of cryopreserved hepatocytes (final cell density 0.5×10 in Williams E medium supplemented with 2 mM L-glutamine and 25 mM HEPES) was added. 6 viable cells / mL) to start the reaction. The final culture volume was 500 μL. Two control compounds were included in each species, along with appropriate vehicle controls. At the appropriate time point, the reaction was stopped by transferring 50 μL of the culture to 100 μL of acetonitrile containing the internal standard. Samples were removed at 6 time points (0, 5, 15, 30, 45 and 60 min) during the 60 min experiment. The termination plate was centrifuged at 2500 rpm for 30 min at 4 ° C to precipitate the protein. After protein precipitation, the sample supernatants were combined in a box of up to 4 compounds and analyzed using universal LC-MS / MS conditions. The gradient of the line was determined based on a plot of the ln peak area ratio (compound peak area / internal standard peak area) versus time. Subsequently, the half-life (t1 / 2) and intrinsic clearance (CL) were calculated. int Compounds with low clearance (>80% retention at 60 min) under the assay conditions are denoted as t 1 / 2 >186min.

[0662] result

[0663]

[0664] Example 130: In vivo pharmacokinetics

[0665] The pharmacokinetics of the compound were studied in rats at doses of 1 mg / kg (IV) and 10 mg / kg (PO).

[0666] Pharmacokinetics in rats

[0667] method

[0668] Methods Male rats [Sprague Dawley (SD)] prepared by jugular vein cannulation surgery were treated with experimental compounds via intravenous administration (IV; n = 3; 1 mg / kg) or oral administration (PO; n = 3; 10 mg / kg). The compounds were formulated as solutions in 40:60 dimethylacetamide: saline (IV administration) and 10% DMSO, 20% cremaphor in water (70%) (PO administration). The animals were observed for any obvious clinical signs or symptoms. Serial blood samples were collected via cannula at 0.02, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after IV administration of the compound, and at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after oral administration of the compound, and plasma was prepared by centrifugation and immediately stored at -80°C. The samples were subsequently thawed and prepared for analysis by precipitation of the protein with acetonitrile and analyzed by tandem LCMS using electrospray ionization using a matrix-matched calibration curve.PK parameters were calculated from the resulting data.

[0669] result

[0670]

[0671] Dog Pharmacokinetics

[0672] The pharmacokinetics of the compound were studied in dogs at doses of 0.5 mg / kg (IV) and 4 mg / kg (PO).

[0673] method

[0674] Male beagles were treated with the experimental compounds by intravenous administration (n=2; 0.5 mg / kg) or oral use (n=2; 3 or 4 mg / kg). The compounds were formulated as solutions in 20% dimethylacetamide / 80% (2-hydroxypropyl)-β-cyclodextrin (20% w / v) (IV administration) or in 10% dimethylacetamide / 90% (2-hydroxypropyl)-β-cyclodextrin (20% w / v) (PO administration). The animals were observed for any obvious clinical signs or symptoms. Serial blood samples were collected from the jugular vein at 0.03, 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after IV administration of the compound, and at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after oral administration of the compound, and plasma was prepared by centrifugation and immediately stored at -80°C. The samples were subsequently thawed and prepared for analysis by precipitation of the protein with acetonitrile and analyzed by tandem LCMS using electrospray ionization using a matrix-matched calibration curve.PK parameters were calculated from the resulting data.

[0675] result

[0676]

[0677]

[0678] Example 131: Aqueous Formulation

[0679] The compound of Example 1 was formulated as a solution in 30% w / v Captisol (ie, sulfobutyl ether-β-cyclodextrin) at pH 4 according to the following procedure.

[0680] A vehicle of 30% w / v Captisol (ie, sulfobutyl ether-β-cyclodextrin) was prepared by weighing the required amount of captisol into a suitable container, adding approximately 80% of the final volume of water and stirring magnetically until a solution was formed. The vehicle was then made up to volume with water.

[0681] An aqueous solution of the compound of Example 1 was prepared by weighing 175 mg of the compound into a suitable container and adding approximately 80% of the required volume of carrier. The pH was adjusted to pH 2 using aqueous hydrochloric acid and the resulting mixture was stirred magnetically until a solution was formed. The formulation was then made up to volume with carrier and the pH was adjusted to pH 4 using aqueous sodium hydroxide.

[0682] Example 132: Tablet Composition

[0683] Tablets, each weighing 0.15 g and containing 25 mg of the compound of the present invention, are prepared as follows:

[0684] Composition for 10,000 tablets

[0685] Compound of the present invention (250 g)

[0686] Lactose (800g)

[0687] Corn starch (415g)

[0688] Talc (30g)

[0689] Magnesium stearate (5g)

[0690] The compound of the present invention, lactose and half of corn starch are mixed. The mixture is then forced through a 0.5 mm mesh sieve. Corn starch (10 g) is suspended in warm water (90 mL). The resulting paste is used to granulate the powder. The granules are dried and broken into small pieces on a 1.4 mm mesh sieve. The remaining amount of starch, talc and magnesium are added, carefully mixed and processed into tablets.

[0691] Example 133: Injectable Formulations

[0692] 200 mg of the compound of the present invention

[0693] Hydrochloric acid solution 0.1M or

[0694] Sodium hydroxide solution 0.1M qs to pH 4.0 to 7.0

[0695] Sterile water up to 10 mL

[0696] The compound of the invention was dissolved in mostly water (35°C-40°C) and the pH was adjusted to between 4.0 and 7.0 with hydrochloric acid or sodium hydroxide as appropriate. The batch was then made up to volume with water and filtered through a sterile microporous filter into a sterile 10 mL amber glass vial (Type 1) and sealed with a sterile cap and seal.

[0697] Example 134: Intramuscular Injection

[0698] 200 mg of the compound of the present invention

[0699] Benzyl alcohol 0.10g

[0700] Tetrahydrofuran polyglycol ether 75 1.45g

[0701] Water for injection qs 3.00mL

[0702] The compound of the present invention is dissolved in tetrahydrofuran polyglycol ether. Then benzyl alcohol is added and dissolved, and water is added to 3 mL. The mixture is then filtered through a sterile microporous filter and sealed in a sterile 3 mL glass vial (type 1).

[0703] Example 135: Syrup Formulation

[0704]

[0705] The compound of the invention is dissolved in a mixture of glycerol and a large portion of purified water. The aqueous sodium benzoate solution is then added to the solution, followed by the sorbitol solution, and finally the flavoring agent. The volume is made up to volume with purified water and mixed thoroughly.

Claims

1. A compound which is a benzodiazepine of formula (I) derivative: in: R 1 and R 2 One of them is H, and the other is hydrogen or a benzodiazepine F at the 9-position of the ring system; (i) T is N, Z is C, and is a key, and and does not exist; or (ii) T is C, Z is N, and is a key, and and does not exist; R 3 is a group selected from the following: C1-C6 alkyl, C6-C 10 Aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, which is unsubstituted or substituted by one or two groups selected from the following: C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkoxyalkyl, C1-C6 trifluoroalkyl, halogen, -OR 8 and -N(R 8 )2, where R 8 is H, C1-C6 alkyl or C3-C6 cycloalkyl, and when there are two, each R 8 The same or different, and -N(R 9 )2, where R 9 The group together with the N atom forms a ring selected from morpholine, piperidine, piperazine and pyrrolidine, said ring being unsubstituted or substituted by C1-C6 alkyl; and R 4 Is a halogen, -OR 6 、-NR 6 R 7 or C1-C6 alkyl, 4- to 10-membered heterocyclic group, wherein for NR 6 R 7 , R 6 is a C1-C6 alkyl group; and wherein, for -OR 6 , when R 6 When it is C1-C6 alkyl, R 6 can be substituted by C1-C6 alkoxy groups, so that R 6 is a C1-C6 alkoxyalkyl group, when R 6 It is C4-C 10 When the heterocyclic group is a C1-C6 alkyl group, the heterocyclic group may be an azetidinyl group substituted by a C1-C6 alkyl group. 6 When it is a C1-C6 alkyl group, one or more H atoms in the alkyl group may be replaced by D; R 7 is H; R 5 It is H; n is 0 or 1; and V is N, and each of W, X, and Y is CH; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R 4 It is the group -OCD3.

3. A compound selected from: 2-[4-(Methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[4-(propan-2-ylamino)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(1-methyl-2,3-dihydroindole-6-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-4-methoxyphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-4-propan-2-yloxyphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[2-Fluoro-4-(methylamino)phenyl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-methylimidazo[1,2-b]pyridazine-3-carboxamide; 6-Chloro-2-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; and N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-(furan-3-yl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-5-methylphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-5-methylphenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(5-chloropyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(5-chloropyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-cyclopropylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-Cyclopropylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(5-Cyclopropylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-5-methylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluorophenyl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2,4-difluorophenyl)-5-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluorophenyl)-7-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluorophenyl)-5-(morpholin-4-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-5-pyrrolidin-1-ylpyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2,3-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2,3-Difluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2,6-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-4-pyrrolidin-1-ylphenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 6-Methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-[5-(trifluoromethyl)pyridin-3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 2-[6-(Cyclopropylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(2-methoxyethyl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-methylpyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-ethoxypyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-ethylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-ethyl-2-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-ethyl-2-methylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-propan-2-ylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(6-Propan-2-ylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[2-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[2-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[4-methyl-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1-methylindazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-methylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(Ethylamino)-2-fluoropyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(3-methylmorpholin-4-yl)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(3-methylmorpholin-4-yl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[2-Fluoro-6-(propan-2-ylamino)pyridin-3-yl]-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[2-fluoro-6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1-methylpyrrolo[2,3-b]pyridin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-morpholin-4-ylpyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-[6-(propan-2-ylamino)pyridin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(6-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-[6-(2-Hydroxy-2-methylpropyl)pyridin-3-yl]-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-fluoropyridin-2-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-morpholin-4-ylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-morpholin-4-yl-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-Fluoro-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; 2-(2-methoxy-6-methylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; 2-(2,4-Difluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 2-(2,4-Difluorophenyl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 2-(2,4-Difluorophenyl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methylimidazo[1,2-b]pyridazine-3-carboxamide; 6-Methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; 6-(Azetidin-1-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-pyridin-3-ylimidazo[1,2-b]pyridazine-3-carboxamide; 6-methyl-2-(2-methylpyridin-4-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(2-methylpyridin-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide; 2-(3-Fluoropyridin-4-yl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(3-fluoropyridin-4-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide; 2-(5-fluoropyridin-3-yl)-6-methyl-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(5-fluoropyridin-3-yl)-6-methylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(5-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide; 6-Methyl-2-(6-morpholin-4-ylpyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methyl-2-(6-morpholin-4-ylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide; 6-(Ethylamino)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(1-methylazetidin-3-yl)oxyimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-(1-methylazetidin-3-yl)oxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-(2-methoxyethoxy)imidazo[1,2-b]pyridazine-3-carboxamide; 6-Methoxy-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenyl-6-(trideuterated methoxy)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-phenylimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-phenyl-6-(trideuterated methoxy)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)-6-methoxyimidazo[1,2-b]pyridazine-3-carboxamide; 6-Chloro-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(2-fluorophenyl)imidazo[1,2-b]pyridazine-3-carboxamide; 6-Chloro-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-(5-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(3-fluoropyridin-4-yl)-6-methoxyimidazo[1,2-b]pyridazine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-6-methoxy-2-(6-methylpyridin-3-yl)imidazo[1,2-b]pyridazine-3-carboxamide; 2-(6-ethylpyridin-3-yl)-6-methoxy-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 6-Ethoxy-2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]imidazo[1,2-b]pyridazine-3-carboxamide; 2-(6-ethylpyridin-3-yl)-N-[(3S)-9-fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-6-( 2 H3) methoxyimidazo[1,2-b]pyridazine-3-carboxamide; 2-(6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl)-N-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine -3-yl]-2-{6-[(3S*)-3-methylmorpholin-4-yl]pyridin-3-yl}pyrazolo[1,5-a]pyrimidine-3-carboxamide; N-[(3S)-9-Fluoro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]-2-(1H-indazol-5-yl)imidazo[1,2-b]pyridazine-3-carboxamide; and pharmaceutically acceptable salts thereof. 4.2-(2-Fluorophenyl)-N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine -3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier or diluent.

6. Use of a compound according to any one of claims 1 to 4 in the manufacture of a medicament for treating or preventing respiratory syncytial virus infection.

7. A method for producing a pharmaceutically acceptable salt according to claim 1, which comprises treating a benzodiazepine of formula (I) according to claim 1 with an acid in a solvent. derivative.

8. The method of claim 7, wherein the acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, ethanesulfonic acid, aspartic acid and glutamic acid.

Citation Information

Patent Citations

  • Benzodiazepine derivatives and pharmaceutical compositions containing them

    WO2004026843A1

  • Benzodiazepines for treating or preventing or preventing RSV infection

    WO2005089770A1

  • Process for preparing benzodiazepines

    WO2005090319A1

  • An antimicrobial compound

    WO2016166546A1

  • Benzodiazepine derivatives as RSV inhibitors

    WO2017015449A1